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Abstract
Abstract
Type III secretion systems are used by many pathogenic bacteria to deliver
effector proteins into host cells. The secretion machinery, also known as the
injectisome, is composed of a basal body anchored in the bacterial membranes
and an external needle. Delivery of the effectors across the host cell membrane
requires, in addition, a set of proteins called the translocators that are exported
by the injectisome itself. The interaction between the needle of the injectisome
and the translocators is currently not understood in detail. In Yersinia, the
translocators are a group of three proteins called YopB, YopD and LcrV. The
two hydrophobic proteins YopB and YopD form a pore in the target cell
membrane, while LcrV assists the assembly of the pore. LcrV is known since
the mid-fifties as the major protective antigen against plague.
Using Scanning Transmission Electron Microscopy (STEM) we showed that
LcrV forms a distinct structure at the tip of the injectisome needle, the tip
complex. The tip complex could be specifically labelled with antibodies directed
against LcrV and could be crosslinked to the YscF needle, demonstrating that
LcrV forms the tip complex. The unique localization of LcrV at the tip of the
injectisome needle explains its crucial role in the translocation process and its
role as the main protective antigen against plague.
The orientation of LcrV within the tip complex was determined by analysis of
tips formed by hybrids between LcrV and its orthologues in Pseudomonas and
Aeromonas, PcrV and AcrV, respectively. The N-terminal globular domain and
the C-terminus of LcrV were found to form the base structure of the tip complex.
By quantitative immunoblot analyses and STEM, we determined that the needle
of the Yersinia enterocolitica E40 injectisome consists of 139+/-19 YscF
subunits and that the tip complex is formed by three to five LcrV monomers. A
pentamer represented the best fit for an atomic model of the tip complex. In
addition, the N-terminal globular domain of the V-antigen is crucial for pore
formation as it mediates the interaction with the translocator YopB.
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1. Introduction
1.1 Type III secretion systems
Type III secretion systems (T3SS) are used by plant and animal pathogens,
including Salmonel la, S h i g e l l a , Y e r s i n i a, enteropathogenic and
enterohemorrhagic Escherichia coli (EPEC, EHEC), Pseudomonas and others
to deliver effector proteins into the host cell cytoplasm (Cornelis, 2006; Galan
and Wolf-Watz, 2006).
Five major families of T3SS can be distinguished (Pallen et al., 2005;
Troisfontaines and Cornelis, 2005) (Figure 1): i) the Ysc-family of T3SS, which
includes among others, the Ysc system of Yersinia, the Psc system of
Pseudomonas aeruginosa and the Asc system of Aeromonas salmonicida, ii)
the Inv-Mxi-Spa family, which includes the Salmonella enterica (SPI-1) and
Shigella spp systems, iii) the Ssa-Esc family, which includes the systems of
Salmonella enterica (SPI-2) and of EPEC and EHEC. The fourth and fifth family
comprise two different Hrp T3SS of plant pathogens. These and the T3SSs that
have been identified in the Rhizobiales family of plant symbionts will not be
further discussed.
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Figure 1: Relationship phylogram of the ATPases of injectisomes and FliI, the ATPase of the
flagellum of E. coli (Troisfontaines and Cornelis 2005).
In Yersinia the T3SS is encoded on a 70 kb plasmid of Yersinia virulence (pYV)
(Figure 2) (Laroche et al., 1984). Three large operons (virA, virB, virC) encode
the structural elements for the formation of the injectisome. The translocators,
which form a pore in the host cell membrane, are encoded in one operon
together with the chaperone of the hydrophobic translocators and a regulatory
protein. The genes of the effectors and their designated chaperones are
distributed all over the pYV plasmid.
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Figure 2: Detailed genetic map of the pYVe227 plasmid of Y. enterocolitica W22703. The genes
are colored according to the part of the apparatus they encode. Genes in green encode the Ysc
secretion machinery and proteins involved in its control, genes in light blue encode the
translocation machinery, genes in dark blue encode the effector Yops and genes in red encode.
their chaperones. Genes in orange are involved in regulation of gene expression, the gene in
brown encodes an adhesin and genes in black encode arsenic resistance proteins.
Taken from Iriarte and Cornelis Chapter 6: The 70-Kilobase Virulence Plasmid of Yersiniae in
Pathogenicity Islands and Other Mobile Virulence Elements (Edited by J.B. Kaper and J.
Hacker, ASM Press 1999).
After delivery to the host cell cytosol, the effectors are involved in inhibition of
phagocytosis (Rosqvist et al., 1991), suppression of the inflammatory response
(Boland and Cornelis, 1998; Schesser et al., 1998; Schulte et al., 1996) and the
induction of apoptosis in macrophages (Mills et al., 1997; Monack et al., 1997),
and thereby allow Yersinia to survive extra-cellularly (Figure 3).
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Even though the machinery of the type III secretion system is structurally
conserved in all pathogens, the effectors and specific adaptations vary to suit
the individual situations.
Figure 3: Schematic representation of the infection process of Yersinia. Prior to host cell
contact the effectors are stored, bound by their chaperones, in the bacterial cytoplasm.
Yersinia establishes contact to the host cell via adhesins and the injectisome. This triggers
the formation of a translocation pore in the host cell membrane. The effectors are
translocated through the injectisome and the pore into the host cell cytoplasm, where they
exert their various functions.
1.2 Structure of the injectisome
The injectisome, also known as needle complex (NC) is composed of more than
25 different structural proteins and shares high homology to the bacterial
flagellum. The flagellum itself contains an intrinsic type III secretion system for
the export of the flagellins forming the hook and filament of the machine
(Blocker et al., 2003).
To date the injectisomes from Shigella, Salmonella and EPEC have been
purified and analyzed by transmission electron microscopy (Blocker et al., 2001;
Kubori et al., 1998; Sekiya et al., 2001; Tamano et al., 2000). The injectisomes
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isolated from all three pathogens strongly resemble each other and are all
composed of two sets of rings; a double ring in the outer membrane and a
double ring in the inner membrane.
In the following the injectisome structure determined by cryo-TEM to a
resolution of 17 Å by Marlovits et al. will be discussed in more detail, since this
is the highest resolution structure available (Marlovits et al., 2004).
The base of the injectisome was found to occur with several well-defined
symmetries, which made single particle averaging difficult. The most abundant
stoichiometries (40%) for the base were complexes with 20-fold and 21-fold
rotational symmetry. It is unlikely that the different symmetries serve different
physiological functions in vivo, but they rather represent a natural
polymorphism. The cylindrical base is 300 Å tall and 240 Å wide and can be
divided into two distinct regions, one localized to the outer membrane (outer
rings), the other to the inner membrane (inner rings). The inner rings are formed
by the polymerization of PrgH and PrgK, whereas InvG forms the outer rings.
Within the base the three proteins PrgH, PrgK and InvG are present in a 1:1:1
molar ratio indicating that they all assemble into the same rotational symmetry.
Comparison of the base (no needle) and the needle complex (base + needle)
revealed several structural differences. A cuplike protrusion, which extends
outward from the basal plate, (part of inner ring 1) is larger in the needle
complex compared to the base (Figure 4A/B). The authors speculate that this
could be the port of entry for secreted proteins or a docking site for the ATPase,
which energizes secretion. On the opposite side the base is closed by a
septum, probably formed by domains of InvG. In the needle complex (base +
needle) the needle protruding to the outside replaces this septum structure.
A socket like structure extending from the basal plate into the cavity of the base
is proposed to form the anchoring point for the inner rod formed by PrgJ (Figure
4C). The authors propose PrgJ as the inner rod protein, since it always co-
purifies with the needle complex and is still present after destruction of the
needle by high pH, indicating that PrgJ is buried in the base (Marlovits et al.,
2004).
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Figure 4: A)  Surface renderings of the structures of the Shigella base, B) Surface
renderings of the structures of the Shigella needle complex (NC), C) Removal of the front
half of the base shows its internal chamber. A socketlike structure, marked by an asterisk,
extends into the chamber’s interior (Marlovits et al. 2004)
The different structural components of the T3SS injectisome, including the tip
complex, which will be discussed later, are summarized in Figure 5.
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Figure 5: Summary of the known structural elements of the T3SS injectisome. A) HrcQB (aa
50-120) from Pseudomonas syringae (Fadouloglou et al., 2004) B) EscJ from EPEC (Yip et al.,
2005b) C) YscC from Yersinia (Burghout et al., 2004b) D) HrcN from Pseudomonas syringae
(Müller et al., 2006) and EscN from EPEC (Zarivach et al., 2007) E) MxiH from Shigella (Deane
et al., 2006) F) LcrV from Yersinia (Derewenda et al. 2004), IpaD from Shigella (Johnson et al.,
2006; Erskine et al., 2006) and BipD from Burkholderia (Erskine et al., 2006).
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The C-ring of the T3SS injectisome has not been clearly visualized so far,
probably because it always detaches in the process of injectisome purification.
By TEM analysis of osmotically shocked bacteria, Blocker et al. show the
presence of a large cytoplasmic bulb beneath the inner membrane rings of the
Shigella basal body, which could represent the C-ring (Blocker et al., 1999).
HrcQB from Pseudomonas syringae shares partial amino acid sequence
similarity to the flagellar C-ring component FliN indicating that this protein could
be part of the C-ring. The conserved residues of HrcQB (aa 50 – 128) were
crystallized and found to form a tetramer that is composed of two tightly bound
homo-dimers (Figure 5A; Fadouloglou et al., 2004).
In Shigella, crosslinking prior to injectisome purification was used to prevent the
dissociation of the C-ring from the basal body. The HrcQB homolog Spa33 was
then to be found associated to the cytoplasmic side of the inner membrane
rings by immuno-TEM (Morita-Ishihara et al., 2006). However, the rather diffuse
images of this region did not allow a detailed structural analysis of the C-ring.
The crystal structure of EscJ from EPEC, the homolog of PrgK (Salmonella) and
YscJ (Yersinia) was published in 2005 by Yip et al.
EscJ can be modeled into a superhelical structure forming a large ring,
consisting of 24 EscJ monomers (Figure 5B). The overall diameter of the ring is
180 Å and the central channel constricts from 120 Å at the membrane face to
73 Å at the periplasmic side. Since EscJ is a lipoprotein and does not have any
transmembrane segments the hypothesis is that the ring is associated to the
periplasmic side of the inner membrane without directly inserting into the
membrane. EscJ could then act as an assembly platform for transmembrane
component that would insert into the free membrane patch inside the EscJ ring
(Yip et al., 2005b).
Proteins of the secretin family form the outer membrane rings of the basal body.
Secretins are outer membrane proteins found in many different systems,
including type II secretion (Chami et al., 2005), type IV pili (Collins et al., 2004)
and filamentous phages (Russel, 1994).
The Yersinia secretin YscC was found to form two rings stacked on top of each
other with an outer diameter of 200 Å and a central pore of 50 Å (Figure 5C;
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Burghout et al., 2004b; Koster et al., 1997). The lipoprotein YscW serves as a
pilot for the correct insertion of YscC into the outer membrane (Burghout et al.,
2004a). InvG and MxiD are the secretins in the Salmonella and Shigella type III
secretion systems, respectively and were shown to form the outer rings of the
needle complex (Blocker et al., 2001; Marlovits et al., 2004).
All the known type III secretion systems also include an associated ATPase,
which shares similarity to the F1-ATPase β subunit. The ATPase is believed to
strip the chaperone from the effectors and energize the export through the
narrow channel of the needle (Akeda and Galan, 2005).
The ATPase HrcN from Pseudomonas syringae was found to associate with the
inner membrane and dodecamerization of the monomers stimulated the ATP
hydrolyzing function (Pozidis et al., 2003). The structure of the dodecamer was
determined to a resolution of 1.6 nm by cryo-electron microscopy and is
composed of two stacked hexameric rings (Figure 5D; Müller et al., 2006).
Based on the model of the basal body presented by Marlovits et al. the authors
propose that the ATPase could dock into the cytoplasmic opening of the basal
body (Müller et al., 2006).
In 2007 Zarivach et al. solved the structure of the ATPase from EPEC to a
resolution of 1.8 Å. For the crystallization the first 102 amino acids of the protein
were deleted. Similar to HrcN, EscN ATP hydrolyzing activity is dependent on
oligomerization, however in this case the ATPase forms a hexamer (Figure 5D;
Zarivach et al., 2007).
Many of the structural and functional aspects and the assembly of the T3SS
injectisome remain unclear. Structure determination is complicated by the fact
that most subunits are membrane proteins, and therefore difficult to purify and
crystallize.
The needle of the T3S machinery is formed by the helical polymerization of a
small protein (YscF in Yersinia, MxiH in Shigella, EscF in EPEC, PrgI in
Salmonella).
The first low-resolution structure of the T3SS needle from Shigella determined
by TEM and X-ray fiber diffraction showed that the needle has the same helical
parameters as the flagellar filament (~ 5.6 subunits/turn, 24 Å helical pitch).
Introduction
12
MxiH contains two long anti-parallel α-helices connected by a loop (PSNP-loop;
Figure 5E; Deane et al., 2006). Similar helices were also found in the D0 portion
of flagellin (Samatey et al., 2001) and the EPEC needle extension EspA (Yip et
al., 2005a), indicating that this feature is important for the assembly of this kind
of helical structure.
A model of the Shigella needle was built by docking the individual MxiH
subunits into the low-resolution structure determined by Crodes et al. (Figure
5E). In this model the C-terminus of each subunit is involved in extensive inter-
subunit contacts. The central channel of the needle (2-3 nm in diameter)
probably only allows secretion of single α-helices or random coil, indicating that
proteins are secreted in a partially unfolded conformation (Deane et al., 2006).
In Yersinia the needle is tightly regulated to a length of 60 nm by a molecular
ruler and is composed of about 140 subunits of YscF (Broz et al., 2007; Journet
et al., 2003). The length of the needle is adapted to the length of bacterial and
host cell surface proteins, which ensures close contact that triggers the export
of the late substrates (pore formers and effectors; Mota et al., 2005).
1.3 Type III secretion translocators
A general feature common to all T3SS, is that two of the translocators have
hydrophobic domains (Blocker et al., 1999; Hakansson et al., 1996), while the
third is hydrophilic. Using hemolysis and dye release experiments, the two
hydrophobic translocator proteins have been shown to form a pore in the host
cell membrane to allow effector translocation (Faudry et al., 2006; Hakansson
et al., 1996; Ide et al., 2001; Neyt and Cornelis, 1999; Warawa et al., 1999). In
addition, the observed pore formation is dependent on the presence of the
hydrophilic translocator protein (Fields et al., 1999; Marenne et al., 2003;
Pettersson et al., 1999).
In all T3SSs studied so far, the three translocators are encoded together in one
large operon (Figure 6). Besides the translocators, the operon also contains a
gene coding for a small protein that serves as a chaperone for the hydrophobic
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translocators, and sometimes a gene encoding a protein involved in the
regulation of T3S.
Figure 6: Organisation of the translocator operons from different type III secretion systems.
The translocators of T3SSs are well conserved within their particular families.
Between families, the similarities are often not found on the sequence level but
are found in functional aspects, reflecting specific adaptations of the pathogenic
bacteria to different environments. The hydrophobic translocators YopB/YopD
of Yersinia and PopB/PopD of P. aeruginosa are sufficiently related for PopB
and PopD to complement mutations in YopB and YopD. However,
complementation is only efficient if the hydrophilic translocator PcrV is provided
together with PopB and PopD (Broms et al., 2003; Frithz-Lindsten et al., 1998),
indicating that even though a certain degree of functionality can be achieved
with proteins from two different systems, the translocators are optimally
adjusted to their partners. IpaB/IpaC of Shigella and SipB/SipC of Salmonella
SPI-1 have the same function as YopB/YopD and PopB/PopD, but homology is
restricted and mainly limited to the hydrophobic domains (Hakansson et al.,
1993).
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For the hydrophilic translocator, sequence conservation is also highest between
proteins of the same T3SS family. LcrV of Yersinia enterocolitica and its
homologs PcrV of P. aeruginosa and AcrV of A. salmonicida are so closely
related that PcrV and AcrV and even mixed hybrid-proteins can form a tip
structure at the end of the Y. enterocolitica needle but this structure is not
always functional with YopB/YopD (Broz et al., 2007; Holmstrom et al., 2001;
Mueller et al., 2005). The hydrophilic translocators from the other T3S families,
like IpaD, SipD, EspA and SseB, exhibit only low sequence similarity to LcrV,
PcrV and AcrV, but share the same function in pore formation.
In many of the described type III secretion systems the hydrophilic translocators
also serve a regulatory role. Yersinia lcrV mutants express and secrete reduced
amounts of translocators (YopB, YopD) and effectors (Marenne et al., 2003;
Skrzypek and Straley, 1995). LcrV also interacts with the negative regulator
LcrG in the bacterial cytosol and possibly titrates LcrG away from the secretion
machinery to open the way for secretion of effectors (Nilles et al., 1997). In
Shigella IpaD and IpaB have been reported to regulate secretion of the other
Ipa proteins and several other proteins in the system (Menard et al., 1994).
1.4 The needle tip complex
The link between the needle and the pore in the target cell membrane remained
unclear for quite some time. First insights into this question came from the
analysis of red blood cell (RBC) membranes isolated after infection with
Y. enterocolitica or P. aeruginosa. The hydrophobic translocator proteins, YopB
and YopD (Yersinia) or PopB and PopD (Pseudomonas), were found inserted in
the membranes, whereas the hydrophilic translocator protein (LcrV, PcrV) was
not (Goure et al., 2005). However, mutants lacking the hydrophilic translocators
did not lyse RBCs, even though slightly reduced amounts of the hydrophobic
translocators still inserted into the membrane (Goure et al., 2005). Antibodies
directed against LcrV or PcrV inhibit pore formation in RBCs infected with Y.
enterocolitica or P. aeruginosa in a dose dependent manner, but not the
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membrane insertion of the hydrophobic translocator proteins (Goure et al.,
2005).
Similar observations were made for IpaD, the hydrophilic translocator protein
from Shigella flexneri. Analysis of the hemolytic activity of ipaD deletion
mutations showed that IpaD is essential for the insertion of the hydrophobic
translocators IpaB/IpaC into RBC membranes (Picking et al., 2005). Deletions
after the first 120 amino acids of IpaD completely abolished the hemolytic
activity. However, deletions between amino acids 41 and 120 only slightly
reduced hemolysis (Picking et al., 2005). In addition, antibodies directed against
IpaD can prevent the insertion of IpaB/IpaC into RBC membranes (Espina et
al., 2006b) and the entry of Shigella into epithelial cells (Sani et al., 2007).
These data support a model in which the hydrophilic translocator, acting as an
extra-cellular chaperone or assembly platform, helps the hydrophobic
translocators to integrate into the eukaryotic cell membrane and form a
functional pore. Protective antibodies probably inhibit the assembly of this pore
by binding to the hydrophilic translocator and preventing its correct interaction
with the other translocator proteins.
Examination of the Y. enterocolitica needle by scanning transmission electron
microscopy (STEM) revealed a novel structure, the tip complex, at the distal
end of wild type needles (Mueller et al., 2005). This feature was not detected on
needles purified from lcrV mutant bacteria. In addition, anti-LcrV antibodies
directly visualised by STEM, bound exclusively to the tip complex, proving that
the hydrophilic translocator itself formed the observed structure (Figure 7A).
Size differences between this protein, LcrV, and its orthologues PcrV and AcrV
from P. aeruginosa and A. salmonicida, respectively, were exploited to gain
further information. As shown in Figure 7B, the Yersinia tip complex comprises
three clearly distinguishable parts, a head, a neck and a base. Tip complexes
formed by PcrV on the Yersinia needle had a smaller base compared to the
LcrV tip complex and were not functional in pore formation in conjunction with
the Yersinia translocators YopB and YopD. The AcrV tip complex had a
structurally altered base and a wider head region, but still promoted the
formation of pores by YopB and YopD (Broz et al., 2007). The analysis of
chimeric V-antigens constructed of LcrV and PcrV or LcrV and AcrV revealed
that chimeras containing the N-terminal region of LcrV or AcrV lead to efficient
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hemolysis and insertion of YopB into red blood cell (RBC) membranes, whereas
chimeras with a PcrV N-terminal region do not (Broz et al., 2007). This indicates
that the N-terminal region of the V-antigen is involved in inserting YopB into the
target cell membrane.
Using immuno-gold labelling and TEM, Espina et al. showed that the hydrophilic
translocator IpaD from Shigella also localizes at the tip of the needle (Figure
7C, left). In contrast to Yersinia, no obvious structure was visible at the tip of
these attached Shigella needles, suggesting that the tip complex is either
unstable or a direct continuation of the needle and therefore difficult to visualize
(Espina et al., 2006b). Later, Sani et al. used a cross-linker to stabilize the tip
complex prior to purification of the needle complex and observed two globular
densities on either side of the needle end (Figure 7C, right) that were absent in
needles from an ipaD mutant (Sani et al., 2007). Unlike LcrV, IpaD cannot be
functionally replaced by its Salmonella SPI-1 orthologue SipD, even though the
two T3SSs belong to the same family (Picking et al., 2005).
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Figure 7: A) STEM images of purified needles from Y. enterocolitica, labelled with anit-LcrV
antibodies (Mueller et al. 2005) B) Averages of the tip complexes formed by LcrV (left), PcrV
(middle) and AcrV (right) (Mueller et al. 2005). C)  Immunogold labelling using anti-IpaD
antibodies on whole bacteria with attached needles (left) (Espina et al. 2006). Average of the
IpaD tip complex obtained by cross-linking (right; Sani et al. 2006).
LcrV, IpaD and the IpaD homologue BipD from Burkholderia have two long
alpha-helices (α7, α12 in LcrV; α3, α7 in IpaD; α4, α8 in BipD) that form a
coiled coil (Figure 8A; Derewenda et al., 2004; Espina et al., 2006a; Espina et
al., 2007; Johnson et al., 2007). A similar coiled coil is found in EspA, and is
necessary for the oligomerization of this protein into a long filament (Yip et al.,
2005a). Besides the coiled coil domain, LcrV also has two large globular
domains. These domains are much smaller in IpaD and BipD, which might
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explain the structural variations in the tip complexes formed by LcrV and IpaD
(Mueller et al., 2005; Sani et al., 2007). The globular domains also have
different sizes in PcrV and AcrV. This fact was exploited in analyses of hybrids
between LcrV and PcrV and LcrV and AcrV. The results showed that the N-
terminal globular domain of LcrV forms the base of the tip complex. Thus, even
though the N-terminal globular domain faces the needle it is either directly or
indirectly involved in the insertion of YopB into the host cell membrane by a so
far unknown mechanism (Broz et al., 2007).
Determination of the orientation of LcrV allowed the structure of the LcrV tip
complex to be modelled by docking the crystal structure of LcrV (Derewenda et
al., 2004) into the average electron density map of the Yersinia tip complex, in
the orientation determined by analysis of the hybrid proteins. Circular symmetry
was assumed and the best fit was obtained with five LcrV per tip complex
(Figure 8B; Broz et al., 2007). In support of this stoichiometry, quantitative
immuno-blots combined with STEM mass-per-length measurements indicated
the presence of 3-5 LcrV molecules in the complex (Broz et al., 2007). In
another study, Deane et al. crystallized the Shigella needle subunit MxiH and
built a model of the assembled needle (Deane et al., 2006) based on earlier
TEM analysis (Cordes et al., 2003; Deane et al., 2006). Assuming that the
Yersinia needle formed by YscF is similar to the Shigella needle, the LcrV tip
complex was modelled by superimposing the C-terminal helix of LcrV on to the
structurally equivalent helix of MxiH at the tip of the needle. The model
suggests that LcrV forms a pentamer continuing the helical architecture of the
needle (Figure 8C; Deane et al., 2006). However, it is also possible that there is
an additional adaptor protein between the needle and the tip complex, which
would allow assembly of the tip complex without continuation of the helical
symmetry of the needle.
So far there is no indication that either of the hydrophobic translocator proteins
forms part of the Yersinia tip complex (Mueller et al., 2005). In contrast, based
on biochemical evidence, immunogold labelling and TEM analysis, it was
proposed that the Shigella tip complex is composed of a tetramer of IpaD and
one copy of the hydrophobic translocator IpaB (Johnson et al., 2007;
Veenendaal et al., 2007). In contradiction, Olive et al. have reported that IpaB is
only present at the tip of the Shigella needle and detectable at the bacterial
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surface after the addition of bile salts to the culture medium (Olive et al., 2007).
In any case, IpaB does not localise at the needle tip in the absence of IpaD
(Olive et al., 2007; Veenendaal et al., 2007). The IpaD tip complex was
modelled by continuing the helix of the needle, which leads to a staggering of
the monomers (Figure 8D). Due to this, the interface between the fifth and the
first monomer is different from the others. This supports the hypothesis that the
last position could be filled by IpaB (Johnson et al., 2007), which is proposed to
have a similar fold to IpaD with an internal coiled coil, but with a larger C-
terminal domain (Johnson et al., 2007). It has been suggested that the
IpaD/IpaB tip complex also acts as a host cell sensor and is necessary to
initiate the formation of the complete translocation pore (Olive et al., 2007;
Veenendaal et al., 2007) possibly by cholesterol sensing of the host cell
membrane (Olive et al., 2007). Thus, at present, it would seem that the
structure of the tip complex might be different in the Yersinia family and the Inv-
Mxi-Spa family, as represented by Shigella/Salmonella. Nevertheless, the tip
complex in both of these families is involved in the correct assembly of a
functional pore in the host cell membrane.
MxiH, the needle subunit from Shigella, is composed of two long α-helices
connected by a Pro-Ser-Asn-Pro turn (PSNP-turn; Deane et al., 2006). The C-
terminal α-helix of MxiH can be divided into a head and tail region. NMR
chemical shift mapping and the analysis of mutants has revealed that residues
in the PSNP-turn and the head region (Asn-43, Pro-44, Leu-47, Tyr-50, Gln-51)
of MxiH are critical for the interaction with the tip complex protein IpaD (Deane
et al., 2006; Zhang et al., 2007). This finding supports the model proposed by
Johnson et al., which was based on structural similarities between the N-
terminal domain of IpaD and MxiH (Johnson et al., 2007; Zhang et al., 2007). In
the same way, an YscF D28A D46A double mutation abolishes effector
translocation into host cells, even though the mutant protein still polymerizes to
form a needle (Torruellas et al., 2005). Sequence alignment of MxiH and YscF
reveals that the point mutations in YscF and the MxiH residues that are
important for interaction with IpaD map to similar regions. The interaction
between the needle and the LcrV tip complex was not investigated for the YscF
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D28A D46A double mutant, but most likely the tip complex does not assemble
anymore, explaining why translocation cannot occur.
Other examples of needle extensions are found in the EPEC and the S.
enterica SPI-2 T3SSs. In EPEC, the protein EscF forms a short needle that is
extended by a long filament of EspA (Knutton et al., 1998, Daniell et al., 2001;
Sekiya et al., 2001). The EspA filament has the same helical architecture as the
needle (5.6 subunits/turn, 24 Å helical pitch). One of its roles is probably to
cross the glycocalyx layer of the intestine to reach the enterocytes surface. Both
the hydrophobic translocators EspB/EspD and EspA are required for
translocation of effectors into host cells (Wachter et al., 1999). Therefore, the
EspA filament and the LcrV and IpaD tip complexes in Yersinia and Shigella,
respectively, have similar functions.
TEM analysis of the surface of S. enterica Typhimurium grown in vitro under
SPI-2 inducing conditions revealed the presence of surface appendages,
composed of a needle that is sheathed with a large irregular proteinaceous
structure. As demonstrated by immunogold analysis, this sheath contains the
hydrophilic translocator SseB and one of the hydrophobic translocators, SseC
(Chakravortty et al., 2005). In vitro such sheath structures might result from
prolonged secretion of the translocators in the absence of contact to a target
cell membrane. Similar needles were detected on ultra-thin section analysis of
S. enterica Typhimurium residing inside macrophage vacuoles. Their sheath
like structure was smaller and restricted to the distal end of the needles
(Chakravortty et al., 2005), suggesting that it could be a type of tip complex.
The detailed structure of the tip complex in different T3SS is not available yet
and could be further defined by techniques such as cryo-electron microscopy,
which allow high-resolution imaging. In addition continuation of the mutational
analysis to determine the interaction between the needle and the tip complex
will give further insight into the function of the latter complex, especially in the
context of translocation pore insertion and triggering of T3S.
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Figure 8: A) Crystal structures of LcrV, IpaD and BipD (Derewenda et al., 2004, Johnson et al.,
2006, Espina et al., 2006). B) Model of the Yersinia enterocolitica tip complex, formed by 5 LcrV
molecules (Broz et al., 2007) C) Model of the LcrV tip complex on the MxiH needle from Shigella
(Deane et al., 2006) D) Model of the IpaD tip complex from Shigella (Johnson et al., 2006).
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1.5 The translocation pore
Defining the structure and composition of the translocation pore inserted into
host cell membranes by live bacteria remains one of the main challenges in the
field of T3S. Osmoprotection experiments done with RBCs infected with
different bacteria lead to an estimated pore diameter of around 2.3 nm (Table 1;
Blocker et al., 1999; Dacheux et al., 2001; Hakansson et al., 1996; Holmstrom
et al., 2001; Ide et al., 2001; Miki et al., 2004; Shaw et al., 2001; Broz and
Cornelis, unpublished data) which fits to the 2.5 nm inner diameter of the
needle (Cordes et al., 2003).
Species Pore size Reference
Shigella flexneri 2.6 nm Blocker et al. 1999
Pseudomonas aeruginosa 2.8 – 3.5 nm Dacheux et al. 2001
EPEC 3.0 – 5.0 nm Ide et al. 2001
Yersinia enterocolitica 2.4 - 3.2 nm Broz and Cornelis, unpublished
Yersinia pseudotuberculsis 1.2 – 3.5 nm Hakansson et al. 1996
Salmonella SPI-1 3.5 nm Miki et al. 2004
Table 1: Pore sizes in different T3SSs, estimated by osmoprotection experiments
In a more physiological context, the macrophage membrane becomes
permeable to small dyes upon infection with a multi-effector mutant strain of
Yersinia (Neyt and Cornelis, 1999). Macrophages preloaded with a low-
molecular-weight fluorescent marker, released the marker but not cytosolic
proteins, indicating the absence of membrane lysis and consistent with the
insertion of a small pore into the macrophage plasma membrane (Neyt and
Cornelis, 1999). In addition, artificial liposomes that had been incubated with Y.
enterocolitica under conditions permissive for Yop secretion contained channels
detectable by electrophysiology (Tardy et al., 1999). Intriguingly deletion of
certain regions in YopD has been reported to disrupt effector translocation
without disturbing the hemolytic activity on RBCs, indicating that the two
processes might involve different parts of YopD (Olsson et al., 2004) and hence
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that hemolysis might not always reflect the capacity to form a functional
translocation pore.
In 2001, Ide et al. reported a TEM analysis of the T3S translocation pore formed
by EPECs (Ide et al., 2001). In this study RBCs were incubated with
concentrated culture supernatant from wild type EPEC and from a T3S deficient
mutant. Images of the RBC membrane showed the presence of a segmented
pore like structure in samples incubated with supernatant from wild type
bacteria but not in samples incubated with supernatant from T3S mutant
bacteria. The structures, which were also analysed by atomic force microscopy
(AFM), had an outer diameter of 55-65 nm and rose up to 20 nm above the
membrane plane (Figure 9). The inner diameter was estimated as 8 nm by
AFM, which is in contrast to the 3-5 nm determined by osmoprotection
experiments. This discrepancy could be explained by a funnel like structure of
the pore, with a larger opening towards the outside of the membrane and a
narrowing to the (inacessible) inside of the membrane (Ide et al., 2001). It must
be stressed, however, that there was no direct evidence that the structures
observed were indeed the T3S translocon.
Figure 9: Exemplary imaging of an individual pore with AFM inserted by EPEC into the plasma
membrane of sheep RBCs. A) Top view of an individual pore in the RBC membrane with the
corresponding profile. B) Profile of the internal canal indicating the measurable inner diameter
(red triangles). The doughnut-like structure is apparently segmented into six to eight subunits.
C) Three dimensional image of a representative single pore (elevation is colour coded) (Ide et
al., 2001).
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An attempt to visualize the P. aeruginosa T3S translocation pore was reported
in 2003 by Schoehn et al. (Schoehn et al., 2003). The two hydrophobic
translocators, PopB/PopD, were purified together with their chaperone PcrH. At
acidic pH, the translocator proteins detach from their chaperone and bind to and
disrupt artificial liposomes. TEM analysis revealed ring-like structures on and
next to the liposomes, with an internal diameter of 4 nm and an external
diameter of 8 nm (Figure 10). However, both PopB and PopD alone and an
equimolar mix of the two proteins led to the formation of comparable ring
structures, which suggests that upon secretion PopB and PopD oligomerise to
form ring-like complexes. Purified, monomeric PcrV did not have an influence
on the formation of these rings (Figure 10).
Figure 10: A) Electron micrograph of liposomes incubated with PopB at pH 5.3, stained with
uranyl acetate. B) Electron micrograph of liposomes incubated with PopD at pH 5.3, stained
with uranyl acetate. C) Electron micrograph of liposomes incubated with PopB and PopD at pH
5.3, stained with uranyl acetate (Schoehn et al., 2003).
Recently the same group (Faudry et al., 2006) showed that liposomes
incubated with purified PopB and PopD are permeabilized due to the formation
of pores. The inner diameter of the pores formed was determined by release-
assays using fluorescein labelled dextrans entrapped in vesicles at self-
quenching concentrations. Dextrans with a hydrodynamic radius (RH) of 2.3 nm
and 3.4 nm were released from vesicles in the presence of PopB and PopD.
However, a dextran with a RH of 6.1 nm was not released, indicating that the
pore is size-selective and that the inner diameter is between 3.4 nm and
6.1 nm. These findings are consistent with the inner diameter of 4 nm observed
for rings formed by PopB and PopD in liposomes (Schoehn et al., 2003) and are
in the range of the pore size of 2.8 nm - 3.4 nm determined by osmoprotection
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(Dacheux et al., 2001). However, the role of the hydrophilic translocator PcrV in
this experimental setting is again unclear and, since it is required for pore
formation in vivo, it is possible that the natural pore is different from the
structures formed by purified, isolated hydrophobic translocators.
1.6 Involvement of the tip complex in the triggering of T3S
The effectors are translocated into the host cell cytoplasm without leakage of
effectors into the extra cellular medium (Persson et al., 1995; Rosqvist et al.,
1994; Sory and Cornelis, 1994). By monitoring light emission from Yersinia
pseudotuberculosis producing luciferase under the control of the yopE
promoter, Pettersson et al. showed that contact with a target cell triggers yop
gene expression, as a result of export of the lcrQ repressor. This demonstrated
for the first time that T3S function is strictly contact dependent (Pettersson et
al., 1996). More recently, by shortening the needle or lengthening the adhesin
YadA from Y. enterocolitica, Mota et al. demonstrated that it is contact between
the needle tip and host cell membrane that triggers T3S (Mota et al., 2005).
However, the mechanism by which contact with a target cell is recognized and
the signal is transmitted to the bacterial cytosol to trigger export of effectors
remains unclear. It is possible that the tip complex and pore are involved in
some way since they are probably one of the first components of the machinery
to establish contact to the target cell. It has been proposed that completion of
the Shigella translocation pore results in conformational changes in the tip
complex and that this modification is relayed through the needle by subunit
interaction to trigger secretion of effectors (Deane et al., 2006). The hypothesis
that IpaB or IpaD induce structural changes in the needle upon host cell contact
is supported by the fact that secretion of effectors by both an ipaB and an ipaD
mutant is constitutive and can not be further induced by an artificial trigger
(Congo red; Veenendaal et al., 2007). This implies that in the absence of a host
cell sensor (IpaB and/or IpaD) the T3SS is not off but constitutively secretes
effectors. Kenjale et al. introduced several mutations in the gene for the
Shigella needle protein MxiH and found that some MxiH variants showed
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constitutive secretion that could not be increased by Congo red (same
phenotype as ∆ipaB and ∆ipaD). One of these, mutation D73A in MxiH has no
negative effect on IpaD association to the bacterial surface. On the other hand
mutations P44A and Q51A in MxiH abolish IpaD surface localisation (Kenjale et
al., 2005). Yersinia mutants with constitutive secretion phenotypes have also
been described (∆yopN, ∆lcrG, ∆tyeA; Boland et al., 1996; DeBord et al., 2001;
Forsberg et al., 1991; Iriarte et al., 1998), but even though the translocators are
known to be involved in regulation (Francis et al., 2001; Williams and Straley,
1998) deleting them does not lead to deregulated secretion. However,
constitutive secretion of effectors has been reported for several point mutations
in the needle subunit YscF (Torruellas et al., 2005).
This led to the conclusion that the needle is involved in both secretion
regulation and sensing of the host cell (Kenjale et al., 2005; Torruellas et al.,
2005), which does not exclude a role of IpaD/LcrV at the needle tip. TEM
analysis of needles formed by MxiH variants that locked the system in different
secretion states without altering the morphology of the needle did not reveal
changes in the helical structure of the needles. This indicates that either the
helical modification of the needle expected to occur after contact of the tip
complex with the host cell membrane is too small to detect, or there is a
different way to relay the trigger signal to the bacterial cytosol (Cordes et al.,
2005).
A recent study shows that the tip complex proteins from the different T3SS
families have different properties. At different pH in the range of pH 3 to pH 8,
IpaD, BipD and SipD appear in three distinct structural forms, which could relate
to the different pH environments the pathogens encounter in the gastrointestinal
tract during infection. In addition, due to negative surface charges, which attract
protons from solution, a lower pH microenvironment exists close to the host cell
membrane (Markham et al., 2008). In contrast, LcrV and PcrV, do not show
structural changes in relation to pH, but their stability increases when the pH is
raised from pH 4 to pH 8 (Markham et al., 2008). Within this sub-family only Y.
enterocolitica enters its host through the gastrointestinal route, other bacteria
like Y. pestis and P. aeruginosa do not. In view of the above, regulation and
trigger mechanisms of the different T3SSs might vary from pathogen to
pathogen, depending on the host environment and are still poorly understood.
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1.7 Translocated effector proteins influence pore formation
Hemolysis assays (Goure et al., 2005) and dye leakage from macrophages
(Neyt and Cornelis, 1999) upon infection with Yersina are valuable tools to
monitor pore formation. However, pore formation can only be observed in a
multi-effector knock out mutant, indicating that what is observed in these assays
is not exactly what occurs in vivo.
In 2001, Viboud and Bliska reported that the effectors YopE and to a lesser
extent YopT have anti-pore formation activity once they have been translocated
into the host cell by the T3SS of Yersinia (Viboud and Bliska, 2001). YopE is a
GTPase activating protein (GAP) for the Rho family of small GTP-binding
proteins (RhoA, Rac1, Cdc42; Black and Bliska, 2000; Von Pawel-Rammingen
et al., 2000) and thereby interferes with actin dynamics and phagocytosis in the
host cell (Rosqvist et al., 1991).
Viboud and Bliska demonstrated that a ∆yopE mutant strain causes more cell
damage due to pores in the host cell membrane (Viboud and Bliska, 2001). In
infections with wild type Yersinia, GTPase activity is rapidly terminated by
translocated YopE, which minimizes the damage of the target cell plasma
membrane during the Yop translocation process by destroying the cytoskeleton
(Viboud and Bliska, 2001).
Along the same lines Shin and Cornelis recently reported that pore formation by
a multi-effector mutant of Y. enterocolitica triggers a pro-inflammatory response
in macrophages (Shin and Cornelis, 2007). Yet, upon infection with the wild
type strain the inflammatory response is blocked by the effectors, again
contributing to the suppression of an inflammatory reaction in favour of the
bacteria (Shin and Cornelis, 2007).
1.8 Protective Antibodies and Vaccine Development
The tip complex forming proteins are at the interface between the pathogen and
the host cell and play a crucial role in the infection process involving T3S. This
makes them exciting targets for the development of vaccines and new anti-
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microbials that specifically aim to inhibit bacterial virulence systems. Although
no anti-microbials have been developed so far, there is already a long history of
vaccines based on the tip complex.
Long before the concept of T3S was established, the V-antigen (LcrV) and W-
antigen were associated with virulence of Yersinia pestis (Burrows, 1956). Only
strains expressing both the V- and W-antigen induced protective immunity
against plague in a mouse infection model. However only antibodies against the
V-antigen (LcrV) provided protection against plague in mice (Lawton et al.,
1963). More recent studies  have confirmed that polyclonal antibodies against
LcrV as well as a monoclonal antibody that recognizes the central domain of
LcrV confer passive protection against experimental infections with Y. pestis
and Y. pseudotuberculosis (Hill et al., 1997; Motin et al., 1994; Roggenkamp et
al., 1997; Une and Brubaker, 1984). By demonstrating that anti-LcrV antibodies
prevent the T3S-dependent cytotoxicity towards cultured cells Pettersson et al.
proposed that the passive immunity conferred by anti-LcrV antibodies is
mediated by specific inhibition of Yop effector translocation (Pettersson et al.,
1999). In favor of this hypothesis, polycolonal anti-LcrV antibodies specifically
inhibit Yersinia mediated RBC hemolysis in a dose dependent manner and
prevent the assembly of the T3S translocation pore (Broz et al., 2007; Goure et
al., 2005). Besides the F1 capsular antigen of Y. pestis, the V-antigen is one of
the components of subunit vaccines that are currently in development against
plague infections (Williamson et al., 1995); where the highest level of protection
was achieved using this combination of both antigens. In addition, encouraging
results have been obtained with a F1-V fusion protein that confers protection
against bubonic as well as pneumonic plague when tested in animal models
(Heath et al., 1998; Williamson et al., 1995; Williamson et al., 1997).
Similar to LcrV, active immunization of mice with PcrV from P. aeruginosa or
passive immunization with anti-PcrV antibodies provides a high level of
protection against lethal infections (Frank et al., 2002; Sawa et al., 1999).
Furthermore, administration of anti-PcrV F(ab’)2 in a P. aeruginosa provoked
sepsis model, significantly reduced the inflammatory response and level of
bacteremia (Shime et al., 2001). Consistent with this, anti-PcrV antibodies
protect cultured cells from the cytotoxic effects caused by translocated effectors
(Sawa et al., 1999) and inhibit translocon assembly in RBC membranes (Goure
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et al., 2004). However, subunit vaccines containing PcrV have not been
analysed in a clinical setting so far (Doring and Pier, 2008).
Much less is known about the antigenic properties of other LcrV homologs but
antibodies raised against AcrV, which is closely related to LcrV, prevent
cytotoxicity in cell culture infection models (Burr et al., 2003).
Animals infected with Shigella flexneri, were shown to develop antibodies
against several antigens encoded on the S. flexneri invasion plasmid, including
the tip complex protein IpaD (invasion plasmid antigen D) (Oaks et al., 1996).
Even though anti-IpaD antibodies can prevent Shigella induced hemolysis of
RBC (Espina et al., 2006b) and the entry of Shigella into epithelial cells (Sani et
al., 2007), vaccines containing IpaD are not available so far (Levine et al.,
2007).
The homolog of IpaD, BipD from Burkholderia was recently evaluated as a
vaccine candidate, but vaccination of mice with the recombinant protein did not
confer any protective immunity against meliodosis (Druar et al., 2008; Stevens
et al., 2004). However, the same authors reported that upon immunization of
mice with live attenuated bacteria a subpopulation of T cells was reactive
against the BipD protein (Haque et al., 2006).
Antibodies against EspA from EPEC, which is considered the functional
counterpart of LcrV, were detected in human maternal milk (Noguera-Obenza et
al., 2003) as well as in the serum of patients infected with EPEC (Li et al.,
1999). In addition anti-EspA antibodies blocked EPEC-induced attaching and
effacing lesions in vitro (La Ragione et al., 2006).
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2. Aim of the Thesis
The needle of the Yersinia enterocolitica type III secretion machinery is known
to be composed of the small protein YscF.
During my master thesis I found that the hydrophilic translocator LcrV co-
purifies with the needle subunit YscF. In addition there were indications from
transmission electron microscopy (TEM) analysis of purified needles that there
is a structure at the needle tip, which is absent in an lcrV mutant. How the
needle interacts with the target cell membrane and how YopB and YopD are
inserted into the target cell membrane to form the translocation pore was still
unclear.
The aim of my PhD project was to show the localization of LcrV at the tip of the
needle and to characterize the structure in more detail.
We also wanted to gain more insight into the interaction between LcrV, YopB
and YopD during the infection process and to establish a protocol for the
purification of the translocation pore formed by YopB and YopD for subsequent
structural analysis.
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3. Results
3.1 The V-Antigen of Yersinia forms a distinct structure at the tip of
the injectisome needle
Mueller C. A.*, Broz P.*, Müller S. A., Ringler P., Erne-Brand F., Sorg I., Kuhn
M., Engel A. and Cornelis G. R.
Science 310: 674-676 (2005)
* These authors contributed equally to the work
Summary
The analysis of needles purified form Yersinia enterocolitica ∆HOPEMTasd
revealed a distinct structure at one end. This was shown to be the tip of the
needle by analysis of needles attached to the bacterial surface. The observed
structure, called tip complex is composed by three regions, a head, neck and
base and was absent on needles purified from lcrV mutant bacteria and was
restored by complementation of the mutation in trans. In addition, the tip
complex could be specifically labeled by anti-LcrV antibodies, proving that LcrV
itself forms the tip complex. Needles purified from the control strains (∆yopN,
∆yopQ, ∆yopBD) had tip complexes equivalent to the wild type.
In a subsequent step, the lcrV mutant was complemented with the LcrV
orthologues, PcrV and AcrV from Pseudomonas aeruginosa and Aeromonas
salmonicida, respectively. The tip complexes formed by PcrV and AcrV on the
Yersinia needle showed a slightly different structure, but still strongly resembled
the wild type tip complex formed by LcrV.
LcrV was identified as the major protective antigen against plague in the mid-
fifties. Due to its location at the tip of the needle, LcrV takes a crucial position in
the system, which helps to explain why antibodies against LcrV prevent
infection.
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Statement of my work:
•  Purification of needles from different strains: ∆HOPEMTa s d,
∆HOPEMNVQ, ∆yopN , ∆y o p Q,  ∆yopBD, ∆HOPEMNVQ+pPcrV,
∆HOPEMNVQ+pAcrV.
• Analysis of needle purications by silver stained SDS-PAGE and Western
Blotting.
• Analysis of needles by TEM.
• Coordination of the collaboration with the group of Prof. A. Engel.
• Contributed in writing the manuscript.
simple orogastric administration. Thus, identi-
fication of inhibitors of virulence represents a
path to anti-infective discovery that is quite dif-
ferent from conventional approaches that target
only bacterial processes that are essential both in
vivo and in vitro. We further predict that drugs
such as virstatin may act synergistically with
conventional antibiotics, because they act
through independent mechanisms to block in
vivo bacterial replication or survival.
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The V-Antigen of Yersinia Forms a
Distinct Structure at the Tip of
Injectisome Needles
Catherine A. Mueller,1* Petr Broz,1* Shirley A. Mu¨ller,1,2
Philippe Ringler,1,2 Franc¸oise Erne-Brand,1,2 Isabel Sorg,1
Marina Kuhn,1 Andreas Engel,1,2 Guy R. Cornelis1.
Many pathogenic bacteria use injectisomes to deliver effector proteins into
host cells through type III secretion. Injectisomes consist of a basal body
embedded in the bacterial membranes and a needle. In Yersinia, translocation
of effectors requires the YopB and YopD proteins, which form a pore in the
target cell membrane, and the LcrV protein, which assists the assembly of
the pore. Here we report that LcrV forms a distinct structure at the tip of the
needle, the tip complex. This unique localization of LcrV may explain its crucial
role in the translocation process and its efficacy as the main protective antigen
against plague.
Type III secretion (T3S) is commonly used by
Gram-negative pathogenic bacteria to intro-
duce effector proteins into target host cells (1).
Yersinia pestis and Y. enterocolitica, causing
bubonic plague and gastroenteritis respec-
tively, share the same T3S system consisting
of the Ysc (Yop secretion) injectisome, or
Bneedle complex,[ and the secreted Yop
(Yersinia outer protein) effector proteins.
Three translocator proteins, YopB, YopD, and
LcrV, are necessary to deliver the effectors
across the target cell membrane (2–5). LcrV is
required for the correct assembly of the
translocation pore formed by YopB and YopD
in the membrane of the target cell (2, 6). LcrV
(also known as V antigen) is a soluble protein
important for virulence (7) and is a protective
antigen against plague (8). Antibodies against
LcrV prevent the formation of the translocation
pore (6) and block the delivery of the effector
Yops (9). The injectisome is composed of a
basal body resembling that of the flagellum
and a needle (10). The needle has a helical
structure (11) and in Yersinia is formed by
the 9.5-kD protein YscF (12, 13).
Transmission electron micrographs of the
surface of Y. enterocolitica E40 bacteria sug-
gested that the injectisome needle ends with a
well-defined structure (fig. S1). To characterize
this structure, we purified needles from multi-
effector knockout bacteria (strain DHOPEMT)
that had been incubated under either secretion-
permissive or -nonpermissive conditions (14),
then analyzed them by scanning transmission
electron microscopy (STEM). A distinct Btip
complex[ was observed for the wild-type
needles, comprising a head, a neck, and a base
(Fig. 1A, arrow, and fig. S2A). The tip structure
was the same in both cases, but more needles
were produced under secretion-permissive
conditions (15). The purified needle fraction
from secreting bacteria was analyzed to deter-
mine the components of the tip complex (fig.
S3A). LcrV, YopD, and the needle subunit
YscF were found. Other proteins included
flagellins, which are usual contaminants of
needle preparations (13). Upon cross-linking of
purified needles, products formed between YscF
and LcrV, suggesting that the latter is a struc-
tural component of the needle (fig. S3B).
The tip complex observed for wild-type
needles was absent from needles prepared from
bacteria deprived of LcrV (DHOPEMNVQ)
(table S1) (16). Instead, this end of the needle
was distinctly pointed (Fig. 1B, asterisk, and fig.
S2B). The tip complex was restored after the
mutation was complemented in trans with lcrVþ
(Fig. 1B, right, and fig. S2B). Needles from
single yopN or yopQ knockout bacteria were
analyzed as controls and displayed the same tip
complex as the wild-type needles (fig. S4).
Thus, the formation of the tip complex involved
LcrV but not YopN or YopQ.
Needles from a yopBD double mutant (15)
were analyzed to exclude the possibility that
YopD and, although not detected on the gels,
the third translocator protein YopB were tip
complex components. The appearance of the
tip complex was unchanged (fig. S4).
When wild-type needles were incubated
with affinity-purified polyclonal antibodies to
LcrV, the latter specifically bound to the tip
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complex, and we observed many examples of
two needles joined tip to tip by a single anti-
body (Fig. 2). No antibodies to LcrV attached
to needles purified from the lcrV mutant strain
(DHOPEMNVQ). Furthermore, antibodies di-
rected against YopB or YopD did not bind to
wild-type needles (17). In contrast, affinity-
purified polyclonal antibodies against YscF
bound to the needle end opposite the tip com-
plex (fig. S5). Together, these results clearly indi-
cate that LcrV forms the observed tip complex.
Pseudomonas aeruginosa and Aeromonas
salmonicida possess an injectisome closely re-
lated to that of Yersinia. Their respective LcrV
orthologs, PcrV (32.3 kD) and AcrV (40.2 kD),
are different in size to LcrV (37.2 kD). The
pcrVþ and acrVþ genes were used to comple-
ment the lcrV deletion in Y. enterocolitica E40
(DHOPEMNVQ). The recombinant bacteria
could assemble translocation pores. Their needles
contained proteins with the size of PcrV and
AcrV (fig. S6) and exhibited distinct tip com-
plexes (Fig. 3). The head and neck domains of
the tip complex formed by PcrV (Fig. 3A, cen-
ter) were similar to those formed by LcrV, but
the base was narrower (fig. S7). The tip com-
plex formed by AcrV was larger (Fig. 3A, right,
and fig. S7), more variable in shape, and more
fragile, being absent or altered for many
needles. This is reflected by the lower resolution
of the AcrV average. In all three cases, a central
channel seemed to permeate both the needle
and the tip complex (Fig. 3B and fig. S7).
That the needle has a defined tip structure
at its distal end, comprising LcrV, is in agree-
ment with previous reports showing that LcrV
is surface-exposed (3, 4) and essential for the
assembly of a functional translocation pore
(6). LcrV may act as an assembly platform for
this pore (fig. S8) (6). The IpaD protein from
Shigella may function in an analogous fashion
(18), although it has no clear sequence homol-
ogy to LcrV. LcrV can also be compared to
the EspA filament of enteropathogenic Esch-
erichia coli, which forms a physical bridge
between the needle and the host cell (19). The
EspA homolog, SseB of Salmonella SPI-2,
forms an undefined sheathlike structure on the
distal end of the T3S needle (20).
The localization of LcrV at the tip of the
needle and its role in the assembly of the pore
may explain the protective action of anti-
bodies to LcrV. Possibly, the antibodies in-
terfere with the function of the tip complex,
impairing the translocation process.
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Bats Are Natural Reservoirs of
SARS-Like Coronaviruses
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Zhihong Hu,2 Huajun Zhang,2 Jianhong Zhang,2
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Bryan T. Eaton,3 Shuyi Zhang,1,6* Lin-Fa Wang3*
Severe acute respiratory syndrome (SARS) emerged in 2002 to 2003 in southern
China. The origin of its etiological agent, the SARS coronavirus (SARS-CoV),
remains elusive. Here we report that species of bats are a natural host of
coronaviruses closely related to those responsible for the SARS outbreak. These
viruses, termed SARS-like coronaviruses (SL-CoVs), display greater genetic
variation than SARS-CoV isolated from humans or from civets. The human and
civet isolates of SARS-CoV nestle phylogenetically within the spectrum of SL-
CoVs, indicating that the virus responsible for the SARS outbreak was a member
of this coronavirus group.
Severe acute respiratory syndrome (SARS)
was caused by a newly emerged coronavirus,
now known as SARS coronavirus (SARS-CoV)
(1, 2). In spite of the early success of etio-
logical studies and molecular characterization
of this virus (3, 4), efforts to identify the ori-
gin of SARS-CoV have been less successful.
Without knowledge of the reservoir host dis-
tribution and transmission routes of SARS-
CoV, it will be difficult to prevent and control
future outbreaks of SARS.
Studies conducted previously on animals
sampled from live animal markets in Guang-
dong, China, indicated that masked palm civets
(Paguma larvata) and two other species had
been infected by SARS-CoV (5). This led to
a large-scale culling of civets to prevent fur-
ther SARS outbreaks. However, subsequent
studies have revealed no widespread infection
in wild or farmed civets (6, 7). Experimental
infection of civets with two different human
isolates of SARS-CoV resulted in overt clin-
ical symptoms, rendering them unlikely to be
the natural reservoir hosts (8). These data sug-
gest that although P. larvata may have been
the source of the human infection that pre-
cipitated the SARS outbreak, infection in this
and other common species in animal markets
was more likely a reflection of an Bartificial[
market cycle in naBve species than an indi-
cation of the natural reservoir of the virus.
Bats are reservoir hosts of several zoonotic
viruses, including the Hendra and Nipah viruses,
which have recently emerged in Australia and
East Asia, respectively (9–11). Bats may be
persistently infected with many viruses but rarely
display clinical symptoms (12). These charac-
teristics and the increasing presence of bats and
bat products in food and traditional medicine
markets in southern China and elsewhere in
Asia (13) led us to survey bats in the search
for the natural reservoir of SARS-CoV.
In this study, conducted from March to
December of 2004, we sampled 408 bats
representing nine species, six genera, and
three families from four locations in China
(Guangdong, Guangxi, Hubei, and Tianjin) af-
ter trapping them in their native habitat (Table
1). Blood, fecal, and throat swabs were col-
lected; serum samples and cDNA from fecal
or throat samples were independently analyzed,
double-blind, with different methods in our
laboratories in Wuhan and Geelong (14).
Among six genera of bat species surveyed
(Rousettus, Cynopterus, Myotis, Rhinolophus,
Nyctalus, and Miniopterus), three communal,
cave-dwelling species from the genus Rhinolo-
phus (horseshoe bats) in the family Rhino-
lophidae demonstrated a high SARS-CoV
antibody prevalence: 13 out of 46 bats (28%)
in R. pearsoni from Guangxi, 2 out of 6 bats
(33%) in R. pussilus from Guangxi, and 5 out
of 7 bats (71%) in R. macrotis from Hubei.
The high seroprevalence and wide distribution
of seropositive bats is expected for a wildlife
reservoir host for a pathogen (15).
The serological findings were corroborated
by poylmerase chain reaction (PCR) analyses
with primer pairs derived from the nucleocapsid
(N) and polymerase (P) genes (table S1). Five
fecal samples tested positive, all of them from
the genus Rhinolophus: three in R. pearsoni
from Guangxi and one each in R. macrotis and
R. ferrumequinum, respectively, from Hubei.
No virus was isolated from an inoculation of
Vero E6 cells with fecal swabs of PCR-positive
samples.
A complete genome sequence was deter-
mined directly from PCR products from one of
the fecal samples (sample Rp3) that contained
relatively high levels of genetic material. The
genome organization of this virus (Fig. 1), ten-
tatively named SARS-like coronavirus isolate
Rp3 (SL-CoV Rp3), was essentially identical to
that of SARS-CoV, with the exception of three
regions (Fig. 1, shaded boxes). The overall
nucleotide sequence identity between SL-CoV
Rp3 and SARS-CoV Tor2 was 92% and in-
creased to È94% when the three variable re-
gions were excluded. The variable regions are
located at the 5¶ end of the S gene (equivalent to
the S1 coding region of coronavirus S protein)
and the region immediately upstream of the
N gene. These regions have been identified
as Bhigh mutation[ regions among different
SARS-CoVs (5, 16, 17). The region upstream
of the N gene is known to be prone to de-
letions of various sizes (5, 16, 18).
Predicted protein products from each gene
or putative open reading frame (ORF) of SL-
CoV Rp3 and SARS-CoV Tor2 were com-
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Materials and Methods
This study was carried out with Y. enterocolitica E40 (1) carrying several mutations on
the virulence pYV plasmid, listed in Table S1.
The oligonucleotides used for the genetic constructions are listed in Table S2.
To delete the complete yopB and yopD genes, flanking regions of the yopB (pYVe227
(accession NC_002120) bp 17702-17196, primers 3854/3862) and the yopD (pYVe227
bp 15076-14861, primers 3863/3861) genes (2) were cloned by overlapping PCR into
pBluescript KS+II with SalI and XbaI restriction sites. The resulting plasmid was called
pISO82 (Table S1). The SalI-XbaI fragment of pISO82 containing the flanking regions of
the yopB and yopD genes was cloned into the same sites of the suicide vector pKNG101
(Table S1), resulting in the mutator plasmid pISO83 (Table S1). The yopB and yopD
genes on the Y. enterocolitica MRS40 pYV plasmid were deleted by allelic exchange
with pISO83 as described previously (3). The resulting Y. enterocolitica mutant pYV
plasmid was called pISO4005 (Table S1).
The lcrV mutation was complemented by plasmid pMN12 containing lcrV+
downstream of the yopE promoter (3).
The pcrV and acrV (4) sequences were amplified by PCR on genomic DNA from
Pseudomonas aeruginosa PAO1 (accession NC_002516, primers 3808/3809) and
Aeromonas salmonicida JF2267 (accession AJ516009, primers 3810/3811). The PCR
products were digested with NcoI/EcoRI and AflIII/EcoRI and cloned into the NcoI/EcoRI
sites of the expression vector pBAD/MycHisA giving plasmids pPB24 and pPB25 (Table
S1).
Bacteria were routinely grown on Luria-Bertani agar plates and in liquid Luria-
Bertani medium. Ampicillin was used at a concentration of 200 µg/ml to select for the
expression plasmids. For the induction of the yop  regulon (secretion permissive
conditions) Y. enterocolitica bacteria were inoculated to an OD600 of 0.1 and cultivated in
brain-heart infusion (BHI; Remel) supplemented with a carbon source, 20 mM MgCl2
and 20 mM sodium oxalate (BHI-Ox) for 2 hours at room temperature, then shifted to
37 °C and incubated for 4 hours (5). To keep the yop regulon in a non-induced state
(secretion non-permissive conditions) bacteria were inoculated to an OD600 of 0.1 and
cultivated in BHI supplemented with a carbon source, 20 mM MgCl2 and 5 mM CaCl2
(BHI-Ca2+) for 2 hours at room temperature, then shifted to 37 °C and incubated for 4
hours.
Expression of the different genes cloned downstream of the pBAD promoter was
induced by adding 0.2 % arabinose to the culture just before the shift to 37 °C, and again
2 hours later. The carbon source was glycerol (4 mg/ml) when expressing genes from the
pBAD promoter, and glucose (4 mg/ml) in the other cases. The supernatant of every
culture used for needle purification was analysed for secreted Yop proteins.
Secreted proteins of all the strains were analyzed by Coomassie stained SDS-
PAGE, to verify that YopB and YopD were well secreted (data not shown). Secreted
proteins were precipitated for 1 hour at 4 °C with trichloroacetic acid 10 % (w/v) final
2and separated by SDS-PAGE. In each case, proteins secreted by 3 x 108 bacteria were
loaded per lane. After electrophoresis, proteins were stained with Coomassie brilliant
blue (Pierce) or transferred to nitrocellulose membranes. Immunoblotting was carried out
using rabbit polyclonal antibodies directed against YscF (MIPA 80) and LcrV (MIPA
220). Detection was performed with secondary antibodies conjugated to horseradish
peroxidase (1:2000; Dako) before development with supersignal chemiluminescent
substrate (Pierce).
To prepare the anti-LcrV antibodies (MIPA 220), lcrV DNA was amplified from
pYV40 DNA (primers 3283/3290). The PCR product was digested with NdeI and
BamHI, and cloned into the expression vector pET28a (Novagen) giving plasmid pPB10
(Table S1). A soluble His-LcrV protein was produced in E. coli BL21 (DE3) pLysS and
purified on chelating sepharose beads (Amersham Biosciences). A rabbit was immunized
by 4 injections with a total of 1 mg of His-LcrV in 20 mM phosphate buffer (CER,
Marloie, Belgium). The serum was affinity-purified on His-LcrV immobilized on
nitrocellulose membranes. The serum was then concentrated on a ProteinG-column
(MabTrap Amersham Biosciences). The Bradford assay (BioRad) was used to determine
the concentration of purified antibodies.
To produce polyclonal anti-YscF antibodies (MIPA 223), yscF DNA was
amplified from pYV40 DNA (primers 3759/3760). The PCR product was digested with
BamHI  and XhoI, and cloned into the expression vector pGEX4T3 (Amersham
Biosciences) giving plasmid pISO66 (table S1). YscF was produced as a glutathione S-
transferase fusion protein encoded by plasmid pISO66. Expression of the protein was
induced in E. coli TOP10 by addition of isopropyl-β-D-thiogalactopyranoside (0.2 mM
final concentration), as soon as the culture reached an OD600 of 0.6. Four hours after
induction, bacteria were collected, lysed by sonication in lysis buffer (PBS, 1 % Triton-
X100, 5mM dithiotreitol, 1 mM phenylmethylsulfonylfluoride and protease inhibitor
cocktail complete Mini (Roche)), and purified by affinity chromatography with
glutathione-Sepharose beads (Amersham Biosciences). The beads were washed five
times with PBS at 4 °C. YscF was eluted from the beads by thrombin cleavage (thrombin
protease 50 units/ml in PBS) for 1 hour at room temperature. The thrombin was then
removed by incubation with benzamidine-Sepharose beads. A rabbit was immunized by 4
injections with a total of 1 mg of YscF (CER, Marloie, Belgium). The serum was purified
on a Protein G-column (MabTrap Amersham Biosciences). The Bradford assay (BioRad)
was used to determine the concentration of purified antibodies.
Hemolytic assays were carried out as described by Goure et al. (6).
To purify needles, Yersinia bacteria were cultivated in non-permissive or
permissive conditions for secretion (3, 5) using the following protocols:
Non-permissive conditions (BHI-Ca2+): Less injectisomes are built under non-permissive
conditions, due to a known feedback regulatory effect (5, 7). Bacteria from 3 litres of
culture were harvested by centrifugation (20 min at 4000 x g) and resuspended in 20 mM
TrisHCl, pH 7.5 (1/30 of the initial culture volume). The bacteria were sheared by
passing the suspension through an 18G needle using a syringe. They were then pelleted
by centrifugation (10 min at 8300 x g). The supernatant was collected and passed through
a 0.45 µm mesh filter (cellulose acetate membrane). The filtrate was concentrated 10 fold
3using an Amicon Stirred Ultraconcentration Cell # 8200 (YM30 membrane (Ultracel YM
= Regenerated Cellulose Acetate, 30K), 5 bar pressure). The supernatant was further
concentrated using a Millipore Ultrafree-15 Centrifugal filter device Biomax-10K and
centrifuged for 30 min at 20000 x g. The pellet, containing needles, was resuspended in
20 mM TrisHCl, pH 7.5 (1/48000 of the initial culture volume) and analyzed by SDS-
PAGE, immunoblotting and electron microscopy.
Permissive conditions (BHI-Ox): Bacteria from 300 ml of culture were harvested by
centrifugation (10 min at 5700 x g) and washed once with 20 mM TrisHCl, pH 7.5 (1/30
of the initial culture volume). The washing supernatant was passed through a 0.45 µm
mesh filter (cellulose acetate membrane) and centrifuged for 30 min at 20000 x g. The
resulting pellet was resuspended in 20 mM TrisHCl, pH 7.5 (1/3000 of the initial culture
volume) and analyzed by SDS-PAGE, immunoblotting and electron microscopy.
For the cross-linking experiments, purified needles were diluted 25 x in 20 mM
TrisHCl, pH 7.5 and put on ice. Glutaraldehyde (Sigma) was added to a final
concentration of 0.4 % (v/v). The cross-linking reaction was allowed to proceed for 15
minutes and was then quenched by the addition of 1 M TrisHCl, pH 8 (1/10 of the
reaction volume). The cross-linked products were analyzed by SDS-PAGE and Western
blotting.
Visualization of the needle-like structures on the cell surface of bacteria was done
by electron microscopy as described by Hoiczyk and Blobel (8). After 4 hours of
induction at 37 °C, bacteria were harvested at 2000 x g and carefully resuspended in 20
mM TrisHCl, pH 7.5. Droplets were adsorbed to freshly glow-discharged, formvar-
carbon coated grids, and negatively stained with 2 % (w/v) uranyl acetate. Bacteria were
visualized in a Philips Morgagni 268D electron microscope at an acceleration voltage of
80 kV.
For scanning transmission electron microscopy (STEM), the purified needles
were diluted with buffer (20 mM TrisHCl, pH 7.5) as required, adsorbed to thin carbon
film, washed on 4 droplets of quartz double-distilled water and stained with 2 % (w/v)
sodium phosphotungstate. Digital dark-field images were recorded using a Vacuum
Generators STEM HB5 interfaced to a modular computer system (Tietz Video and Image
Processing Systems GmbH, D-8035 Gauting). The microscope was operated at 100 kV
and a nominal magnification of 500000 x, using doses that ranged between 9000 and
13000 electrons/nm2. The contrast was reversed to show protein in bright shades in the
figures.
To calculate the averages of the tip complexes, subframes were manually selected
from the STEM dark-field images recorded at a nominal magnification of 500000 x and
angularly and translationally aligned to an arbitrary reference using the SEMPER
program package (9). A first average calculated from 52-95 aligned subframes was two-
fold symmetrized along the cylinder axis and used to calculate a refined average. Those
subframes that had a cross-correlation value > 0.65 were included in the final average; 65
of the 95 initially selected for the wt, 36 of 52 for the PcrV ortholog, and 35 of 58 for the
AcrV ortholog. A two-fold symmetry was then applied. The resolution was determined
from the Fourier ring correlation function of the independent averages calculated from
the odd and even numbered subframes applying the 0.5 criterion.
4For the immuno-electron microscopy experiments, 5 µl aliquots of the purified
needles suspended in 20 mM TrisHCl, pH 7.5 were incubated for 45 min with 2.5 µl of
antibody solution at room temperature, and diluted up to 20 x with buffer immediately
before grid preparation. In each case, both the initial antibody concentration employed
and the dilution made before adsorption were adjusted to obtain optimum imaging
conditions (sufficient needles and a low background of free antibodies) even though a
large excess of antibodies was used for the reaction. The following, affinity purified,
rabbit polyclonal antibodies were used: anti-LcrV (0.268 mg/ml, MIPA 220), anti-YopD
(0.04 mg/ml, MIPA 24), anti-YopB (0.7 mg/ml, MIPA 38) and anti-YscF (1.4 mg/ml,
MIPA 223).
5 Figures
Figure S1
Fig. S1 Transmission electron micrograph of Y. enterocolitica E40 strain ΔHOPEMT
negatively stained with 2 % uranyl acetate. Needles protrude from the cell surface and
have a distinct structure at their tip (arrow). Scale bar: 40 nm.
6Figure S2
Fig. S2 Galleries showing the tip complexes of needles detailed in Fig. 1. Scale bars: 10
nm. (A) Tip complex of wt needles formed under secretion-permissive (S+) and non-
permissive (S-) conditions. (B) Tip complex of needles formed by the lcrV mutant (∆V
needles) and the lcrV mutant complemented with lcrV+ (∆V+LcrV needles).
7Figure S3
Fig. S3 (A) Silver stained SDS-PAGE (top) and Western blots (bottom) of the needles
purified from different Y. enterocolitica strains. The black arrowheads indicate the bands
corresponding to LcrV (37.2 kDa), YopD (33.2 kDa) and YscF (9.5 kDa). The flagellin
contamination is marked by a white arrowhead. (B) Cross-linking with glutaraldehyde.
Purified needles were incubated with 0.4 % (v/v) glutaraldehyde for 15 minutes and
analyzed by SDS-PAGE and Western blotting with anti-LcrV and anti-YscF antibodies:
NC, not cross-linked; X, cross-linked. The arrowheads indicate cross-linked products of
LcrV. The lowest of these bands corresponds to a complex of about 45 kDa i.e., one LcrV
and one YscF. Cross-linking of the needle subunit YscF lead to a ladder-like pattern as
expected.
8Figure S4
Fig. S4 Images and compiled galleries showing the tip complexes of needles isolated
from yopN (∆N), yopQ (∆Q), yopBD (∆BD) mutants. Scale bars: 10 nm.
9Figure S5
Fig. S5 Anti-YscF antibody labeling of wt needles imaged by dark-field STEM. Clusters
of antibodies bind to the needle ends that do not have a tip complex, sometimes also
linking two needles together. The sides of the needles were not labelled. Presumably the
helical packing of YscF in the needle effectively buries all reactive epitopes. Scale bar:
20 nm.
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Figure S6
Fig. S6 LcrV-orthologs from P. aeruginosa and A. salmonicida transcomplement the lcrV
mutant of Y. enterocolitica (A) Coomassie stained SDS-PAGE of proteins secreted by Y.
enterocolitica ∆HOPEMNVQ (∆V), ∆HOPEMNVQ complemented with LcrV
(∆V+LcrV), ∆HOPEMNVQ complemented with PcrV from P. aeruginosa (∆V+PcrV)
and ∆HOPEMNVQ complemented with AcrV from A. salmonicida (∆V+AcrV). (B)
Lytic activity on red blood cells after 2 hours of contact with Y. enterocolitica
∆HOPEMN (LcrV), ∆HOPEMNVQ+PcrV (∆V+PcrV) and ∆HOPEMNVQ+AcrV
(∆V+AcrV). (C) Silver stained SDS-PAGE (top) and Western blotting (bottom) of the
purified needles from Y. enterocolitica ∆HOPEMNVQ transcomplemented with the
LcrV-orthologs from P. aeruginosa (PcrV; 32.2 kDa) and A. salmonicida (AcrV; 40.2
kDa). AcrV and flagellin are of similar molecular weight.
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Figure S7
Fig. S7 Profiles perpendicular to the needle axis calculated from the averages of PcrV
(A) and AcrV (B) tip structures. The locations of the profiles are the same as for the wt
tip structure shown in Fig. 3. A central channel is indicated by the dip in the profile
evident in all except the neck profile from the AcrV complex. The magnitude of the
central dip is related to the resolution of the average and to the ratio of inner to outer
radius of the cylindrical structure (16). Scale bar: 5nm in (A) and (B).
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Figure S8
Fig. S8 Hypothetical model of the function of the LcrV tip complex. (A) No contact to
host cell: LcrV forms the complex at the tip of the needle. This implies that LcrV is
exported before contact with a target cell (or before secretion is triggered by Ca2+-
chelation) and hence that LcrV has a special status in the export hierarchy. However, it is
not yet known whether LcrV is present at the tip while the needle grows or whether it is
installed at the tip when the needle has reached its final length. Although localized at the
tip of the needle, LcrV does not act as a polymerizing cap, like the hook- and filament-
caps of the flagellum (17), because the needle subunits assemble normally in its absence
(Fig 1B). YopN is not present at the tip of the needle as shown in Fig S4 and by work of
others (18) (B) Contact with host cell membrane: The tip complex assists the assembly of
the translocation pore, serving as an assembly platform.
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Tables
Plasmid Current
designation
Relevant characteristics References
pYV plasmids
pYV40 wt pYV plasmid of Y. enterocolitica E40 (10)
pIML421 ∆HOPEMT pYV40 yopE21yopH∆1-352yopO∆65-558
yopP23yopM23yopT135
(11)
pMN4003 ∆HOPEMNVQ pYV40 yopE21 yopH∆1–352yopO∆65-558
yopP23yopM23yopN45lcrV∆6-319 yopQ17
(3)
pIM417 ∆HOPEMN pYV40 yopE21 yopH∆1–352yopO∆65–558
yopP23yopM23yopN45
(12)
pIM41 ∆N pYV40 yopN45 (13)
pABL402 ∆Q pYV40 yopQ17 (14)
pISO4005 ΔBD pYV40 yopB yopD This work
Clones and vectors
pBAD/Myc-HisA Invitrogen
pET28a Novagen
pGEX4T3 Amersham
pISO66 pGEX4T3 yscF+ This work
pISO82 pBluescriptKS+IIpYVe227bp17702-
17196/bp15076-14861
This work
pISO83 pKNG101pYVe227bp17702-
17196/bp15076-14861
This work
pKNG101 Suicide vector
oriR6K,secBR+,oriTR2K,strAB
(15)
pMN12 pBBR1MCS-2 pyopElcrV+ (3)
pPB10 pET28a-lcrV+ This work
pPB24 pBAD/Myc-HisA-pcrV+ This work
pPB25 pBAD/Myc-HisA-acrV+ This work
Table S1 Plasmids used in this study.
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Codes Oligonucleotides Underlined sites
3808 ATCATGCCATGGCAGAAGTCAGAAACCTTAATGCC NcoI
3809 CCGGGCGAATTCCTAGATCGCGCTGAGAATGTC EcoRI
3810 TGCCCACATGTCAAGCACAATCCCTGACTACAAC AflIII
3811 CCGGGCGAATTCTCAAATTGCGCCAAGAATGTC EcoRI
3283 GATCGGATCCTTACCTCGTGTCATCTAG BamHI
3290 GGGAATTCCATATGATTAGAGCCTACGAA NdeI
3759 GATCGGATCCATGAGTAATTTCTCTGGGTTTAC BamHI
3760 GATCCTCGAGTTATGGGAACTTCTGTAGGATG XhoI
3854 ATCATGGTCGACATGCAACAAGAGACGACAGAC SalI
3861 ATCATGTCTAGACAGGTCTTGAGCTACTACATG  XbaI
3862 TTAACTAACCAAGGTCATAAATGGTCATGGGTTATC
AACGCACTCATG
3863 CATGAGTGCGTTGATAACCCATGACCATTTATGACCT
TGGTTAGTTAA
Table S2 Oligonucleotides used in this study.
15
References
1. M. P. Sory, G. R. Cornelis, Mol. Microbiol. 14, 583 (1994).
2. M. Iriarte, G. R. Cornelis, in Pathogenicity islands and other mobile virulence
elements J. B. Kaper, J. Hacker, Eds. (American Society for Microbiology,
Washington DC, 1999) pp. 91.
3. M. N. Marenne, L. Journet, L. J. Mota, G. R. Cornelis, Microb. Pathogen. 35, 243
(2003).
4. S. E. Burr, K. Stuber, J. Frey, J. Bacteriol. 185, 6583 (2003).
5. G. Cornelis, J. C. Vanootegem, C. Sluiters, Microb. Pathogen. 2, 367 (1987).
6. J. Goure, P. Broz, O. Attree, G. R. Cornelis, I. Attree, J. Infect. Dis. 192, 218
(2005).
7. J. Pettersson et al., Science 273, 1231 (1996).
8. E. Hoiczyk, G. Blobel, Proc. Natl. Acad. Sci U.S.A. 98, 4669 (2001).
9. S. A. Müller, K. N. Goldie, R. Bürki, R. Häring, A. Engel, Ultramicroscopy 46,
317 (1992).
10. M. P. Sory, A. Boland, I. Lambermont, G. R. Cornelis, Proc. Natl. Acad. Sci. U.
S. A. 92, 11998 (1995).
11. M. Iriarte, G. R. Cornelis, Mol. Microbiol. 29, 915 (1998).
12. C. Neyt, G. R. Cornelis, Mol. Microbiol. 33, 971 (1999).
13. A. Boland et al., EMBO J. 15, 5191 (1996).
14. A. Boland, G. R. Cornelis, Infect. Immun. 66, 1878 (1998).
15. K. Kaniga, I. Delor, G. R. Cornelis, Gene 109, 137 (1991).
16. A. C. Steven, B. L. Trus, P. M. Steinert, J. S. Wall, Proc. Natl. Acad. Sci. U. S. A.
81, 6363 (1984).
17. R. M. Macnab, Annu. Rev. Microbiol. 57, 77 (2003).
18. F. Ferracci, Schubot F. D., Waugh D. S., Plano, G. V., Mol. Microbiol. 57, 970
(2005).
Results
33
3.2 Function and molecular architecture of the Yersinia injectisome
tip complex
Broz P.*, Mueller C. A.*, Müller S. A., Philippsen A., Sorg I., Engel A. and
Cornelis G. R.
Molecular Microbiology 65(5), 1311-1320 (2007)
* These authors contributed equally to the work
Summary
Although LcrV (V-antigen) was shown to form the tip complex of the injectisome
needle the orientation, stoichiometry and exact function of LcrV remained
unclear.
Based on the electron density map and crystal structure of LcrV, the protein
could be oriented in two different ways with the N-Terminus forming either the
base or the head of the tip complex.
The size differences between LcrV, PcrV and AcrV are restricted to the two
globular domains of the proteins. Analysis of tip complexes formed by hybrids
between LcrV and PcrV and LcrV and AcrV in which the N-terminal globular
domains were exchanged, revealed that the N-terminal globular domain forms
the base of the tip complex. The stoichiometry of LcrV within the tip complex
was determined using information gained by STEM mass-per-length
measurements of wild type needles and quantitative immunoblots. Together
this data allowed the molecular ratio of YscF and LcrV in purified needles to be
defined indicating a stoichiometry fo 3 – 5 LcrV per tip complex. The tip
complex was modeled by docking the crystal structure of LcrV into the average
electron density map and the best fit was obtained with 5 LcrV per tip complex.
Further analysis of tip complexes formed by hybrids between LcrV/PcrV or
LcrV/AcrV showed that the N-terminus of the V-antigen is important for the
insertion of YopB into the target cell membrane. Hybrid tips comprising the N-
terminus from PcrV did not insert YopB into membranes, whereas hybrids with
the N-terminus from either LcrV or AcrV did.
Results
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Statement of my work:
• Hemolysis experiments.
• Analysis of membrane insertion of YopB and YopD.
• Protein purification for Far-Western Blotting.
• Needle purification for STEM mass-per-length measurements and
quantitative Western Blots.
• Contributed in writing the manuscript.
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Summary
By quantitative immunoblot analyses and scanning
transmission electron microscopy (STEM), we deter-
mined that the needle of the Yersinia enterocolitica
E40 injectisome consists of 139  19 YscF subunits
and that the tip complex is formed by three to five
LcrV monomers. A pentamer represented the best fit
for an atomic model of this complex. The N-terminal
globular domain of LcrV forms the base of the tip
complex, while the central globular domain forms the
head. Hybrids between LcrV and its orthologues PcrV
(Pseudomonas aeruginosa) or AcrV (Aeromonas
salmonicida) were engineered and recombinant
Y. enterocolitica expressing the different hybrids
were tested for their capacity to form the transloca-
tion pore by a haemolysis assay. There was a good
correlation between haemolysis, insertion of YopB
into erythrocyte membranes and interaction between
YopB and the N-terminal globular domain of the tip
complex subunit. Hence, the base of the tip complex
appears to be critical for the functional insertion of
YopB into the host cell membrane.
Introduction
Type III secretion is a system used by many pathogenic
Gram-negative bacteria to deliver effector proteins into
the cytosol of host cells (Cornelis and Wolf-Watz, 1997;
Cornelis, 2006; Galan and Wolf-Watz, 2006). The secre-
tion machinery, also known as the injectisome, is com-
posed of a basal body embedded in the two bacterial
membranes and an external needle, protruding from the
bacterial surface. The injectisome is sufficient to export
proteins across the two bacterial membranes but not
across the host cell membrane. The latter event requires,
in addition, a set of three proteins called the translocators
(Rosqvist et al., 1994; Boland et al., 1996; Fu and Galan,
1998; Fields et al., 1999; Pettersson et al., 1999; Nikolaus
et al., 2001; Marenne et al., 2003), which are exported by
the injectisome itself. Two translocators, YopB and YopD
in Yersinia, are hydrophobic and form a pore in the target
cell membrane (Hakansson et al., 1996; Blocker et al.,
1999; Neyt and Cornelis, 1999; Warawa et al., 1999). The
third translocator, LcrV in Yersinia, is hydrophilic and
assists the assembly of this pore (Goure et al., 2004;
Goure et al., 2005; Picking et al., 2005). LcrV is known
since the mid-1950s as an antigen protective against
plague and is also called V-antigen (Burrows and Bacon,
1956).
Using scanning transmission electron microscopy
(STEM) we have recently demonstrated that LcrV forms
a distinct structure at the tip of the injectisome needle,
the tip complex (Mueller et al., 2005). This unique local-
ization of LcrV at the tip of the injectisome needle
explains its crucial function in the translocation process
and its role as the main protective antigen against
plague. IpaD, the hydrophilic translocator in Shigella,
has recently also been shown to be associated with the
tip of the type III secretion needle (Picking et al., 2005;
Espina et al., 2006; Johnson et al., 2007; Sani et al.,
2007). In spite of very limited sequence similarity, mono-
meric LcrV, IpaD and BipD, the orthologue from
Burkholderia pseudomallei, show a surprisingly close
structural relationship (Derewenda et al., 2004; Erskine
et al., 2006; Johnson et al., 2007). In enteropathogenic
Escherichia coli, the needle is extended by a long fila-
ment made of the LcrV orthologue EspA, rather than by
a more compact tip complex (Knutton et al., 1998;
Daniell et al., 2001). The predominant structural motif
found in all four proteins is a coiled-coil that connects
two more or less globular domains (Derewenda et al.,
2004; Erskine et al., 2006; Johnson et al., 2007). This is
especially obvious in the case of the dumbbell-shaped
LcrV (Fig. S1A; Derewenda et al., 2004), which consists
of two large globular domains that are connected by a
coiled-coil formed by a-helices a7 and a12. EspA also
contains two long a-helices (Yip et al., 2005). In this
article, we address the question of how LcrV assembles
to form the tip complex of the Yersinia injectisome
needle and which parts of the V-antigen are involved in
the formation of the translocation pore.
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Results
Stoichiometry of the tip complex
To estimate how many molecules of LcrV form the tip
complex, we first determined how many YscF monomers
(9.5 kDa) are present in the needle. The mass-per-length
of wild-type (wt) needles, determined by STEM, was
22.9  1.5 kDa nm-1, which corresponds to 2.4  0.2
YscF subunits nm-1 (Fig. 1A), similar to the 2.3 MxiH sub-
units nm-1 determined for the Shigella needle (Cordes
et al., 2003). The total length of 95 negatively stained wt
needles, measured by STEM, was 66  7 nm, consistent
with the wt needle length measured by conventional
transmission electron microscopy, 67  11 nm (Sorg
et al., 2007). As the Yersinia enterocolitica E40 tip is about
8 nm long (Mueller et al., 2005), we estimate that the
needles are composed of 139  19 YscF subunits. Next,
dilutions of known amounts of purified YscF and His-LcrV
were compared with the YscF and LcrV content of purified
needles (Fig. 1B). The molar ratio of LcrV and YscF in
wt needles was found to be 1 LcrV per 32  7 YscF
monomers, leading to an estimate of 4.3  1.1 molecules
of LcrV per tip.
Hybrids between LcrV and its orthologues form
functional tip complexes in Y. enterocolitica
To determine the function of the different domains of LcrV
in the tip complex, we took advantage of size differences
between LcrV (37.6 kDa) and its orthologues, PcrV
(32.3 kDa) from Pseudomonas aeruginosa and AcrV
(40.2 kDa) from Aeromonas salmonicida. These two
orthologues form complexes at the tip of YscF needles
and these complexes are, respectively, smaller and larger
than those formed by LcrV (Mueller et al., 2005). Align-
ment of the three protein sequences reveals that the size
differences are restricted to the two globular domains of
the proteins (residues 1–145 and 183–278 in LcrV), while
the two long helices a7 and a12 that form a coiled-coil
connecting the globular domains are conserved (Fig.
S1B). The N-terminal domain of LcrV is distinctly globular
and only connected to the rest of the protein by a short
Fig. 1. A. Calculation of the mass-per-length of Y. enterocolitica needles. Typical STEM dark-field image recorded from the unstained wt
needles, for mass measurement (left) and histogram showing the mass-per-length (MPL) values (right). The Gauss curve peaks at a value of
22.9  1.5 kDa nm-1 (n = 124; standard error = 0.1 kDa nm-1; overall uncertainty = 1.1 kDa nm-1, considering the +5% uncertainty of the
calibration). The width of the unstained filaments at half the height of their mass profile was 6.6  0.7 nm. This underestimate of the total
width is in good agreement with the dimensions measured by negative stain microscopy.
B. Quantification of the LcrV and YscF content of purified needle fractions. Known amounts of His-LcrV and YscF as well as purified wt
needles from Y. enterocolitica E40 bacteria were separated by SDS-PAGE, transferred to nitrocellulose membranes and subjected to
immunoblot analysis using anti-LcrV and anti-YscF antibodies. The intensity of the LcrV and YscF protein bands was analysed by scanning
the films and subsequent quantification of the pixel intensities using ImageJ 1.33u. The number of molecules of LcrV and YscF in the needle
fraction was determined by comparing the intensities of signals in the needle fraction with signals of purified His-LcrV and YscF standards.
The amount of purified YscF and His-LcrV is indicated in nanograms of protein. Black arrows indicate where the purified needles (NP) match.
The quantification was carried out in three independent experiments, giving a molar ratio of 32  7 molecules of YscF per molecule of LcrV.
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loop, making it an ideal target for domain exchange. We
engineered hybrids between LcrV, PcrV and AcrV that
consisted of the N-terminal domain of one protein and the
a-helices and C-terminus of another protein. Four hybrid
proteins, in the following called LcrV–PcrV, PcrV–LcrV,
LcrV–AcrV and AcrV–LcrV, were generated (Fig. S2B). To
check whether these proteins were functional in Yersinia,
the hybrid genes were used to complement the lcrV
deletion in multimutant Y. enterocolitica DHOPEMNVQ
bacteria. This genetic background, and especially the
yopQ and yopN mutations, was selected because it
allows an optimal detection of pore formation (Marenne
et al., 2003; Goure et al., 2005).
All hybrid proteins were detected in comparable
amounts in the culture supernatant of Y. enterocolitica
incubated at 37°C (data not shown). The ability of PcrV,
AcrV and the hybrid proteins to form functional tip com-
plexes was tested by measuring pore formation in a
haemolysis assay (Goure et al., 2005). The haemolytic
capacity of DHOPEMNVQ bacteria complemented with wt
lcrV was taken as a reference. As shown in Fig. 2A, acrV
but not prcV could complement the lcrV mutation. As
expected, the two hybrids LcrV–AcrV and AcrV–LcrV
were as efficient as LcrV. Interestingly, the hybrid LcrV–
PcrV induced haemolysis but the hybrid PcrV–LcrV did
not. Thus, whenever the N-terminal domain originated
from LcrV or AcrV, the recombinant bacteria induced
levels of haemolysis similar to those induced by bacteria
endowed with wt LcrV. In contrast, when the N-terminal
domain was from PcrV the haemolysis was reduced to
low levels as observed with wt PcrV. This suggests that
the N-terminal domain of the V-antigen determines the
efficacy of pore formation. Such an effect might be direct,
i.e. the N-terminal domain itself interacts with the pore
components YopB and YopD or it could be indirect, i.e. the
N-terminus is required for the stability of the whole tip
complex and thus affects its pore-forming ability.
The N-terminal domain of LcrV acts as an assembly
platform for the functional insertion of the translocators
into the host cell membrane
To further investigate the haemolysis efficiency of the
hybrids and the influence of the N-terminal domain of the
V-antigen, red blood cell (RBC) membranes were isolated
after haemolysis. The amounts of YopB and YopD
inserted into the membranes by DHOPEMNVQ bacteria
producing the different hybrids were analysed by Western
blot (Fig. 2B). YopD was inserted into membranes of
RBCs to a similar extent in all cases. In contrast, when
there was no haemolysis (with PcrV and PcrV–LcrV), the
amount of YopB inserted into the membranes was dra-
matically reduced (Fig. 2B) and instead YopB was found
in the supernatant of the haemolysis assay (Fig. 2C). All
constructs that induced strong haemolysis inserted YopB
into membranes to the extent that no YopB was detected
in the supernatant of the haemolysis assay. These results
suggest that the N-terminal domain of LcrV or AcrV is
necessary for the efficient insertion of YopB into the host
Fig. 2. A. Lytic activity on red blood cells after 2 h of contact with
Y. enterocolitica DHOPEMNVQ bacteria complemented with either
LcrV, PcrV, AcrV or the hybrid proteins. Values of three individual
experiments.
B. Western blots anti-YopB or anti-YopD of isolated red blood cell
membranes after infection with DHOPEMNVQ bacteria
complemented with LcrV, PcrV, AcrV or the hybrid proteins.
The DHOPEMN strain was used as control.
C. Western blots anti-YopB or anti-YopD of the supernatant of red
blood cells infected with DHOPEMNVQ bacteria complemented with
LcrV, PcrV, AcrV or the hybrid proteins. The DHOPEMN strain was
used as control. The background fuzzy band at the level of YopB
and above is artefactual and corresponds to haemoglobin, which is
very abundant in haemolysed samples.
Yersinia injectisome tip complex 1313
© 2007 The Authors
Journal compilation © 2007 Blackwell Publishing Ltd, Molecular Microbiology, 65, 1311–1320
cell membranes. The smaller N-terminal domain of PcrV
lacks this ability, although it has it for its native substrate
PopB.
The results presented so far suggest that the N-terminal
domain of LcrV acts as an assembly platform for YopB,
which is in good agreement with our previous data showing
that LcrV interacts with YopB and YopD (Sarker et al.,
1998). As the N-terminal domain of LcrV is critical for the
insertion of YopB, we tested whether this domain is also
critical for the interaction of LcrV with YopB. The level of
interaction between the LcrV hybrids and YopB or YopD
was monitored by far-Western blotting. Proteins from the
supernatants of Y. enterocolitica cultures incubated in con-
ditions that are permissive for Yop export and containing
the translocators YopB and YopD were separated using
SDS-PAGE and blotted on nitrocellulose membranes. The
membranes were incubated with equimolar amounts of
purified His-tagged LcrV, PcrV, AcrV or hybrid proteins and
analysed with anti-His antibodies (Fig. S3). LcrV interacted
with YopB, YopD and LcrV itself. AcrV, as well as both
hybrids between AcrV and LcrV, also bound YopB and
YopD. However, in good correlation with the haemolysis
data and the membrane insertion of YopB, PcrV and PcrV–
LcrV showed no clear interaction with YopB and YopD
(Fig. S3). Altogether these results support the hypothesis
that the N-terminal domain of the V-antigen functions as an
assembly platform for the folding of the hydrophobic trans-
locators and their subsequent insertion into the host cell
membrane.
Analysis of the hybrid tip complexes
When modelling the LcrV molecule into the structure of
the tip complex, LcrV can be orientated with either the
N-terminal or the central globular domain forming the
base. In the hybrid proteins, the highly conserved coiled-
coil remained unchanged while one of the globular
domains was significantly smaller or larger than that of wt
LcrV. We speculated that STEM images of the tip com-
plexes formed by these hybrid proteins would reveal
these differences and allow the orientation of LcrV in the
tip complex to be defined. We purified the needles from
bacteria expressing LcrV, PcrV, AcrV or the hybrid LcrV
proteins and analysed their tip complex by STEM. The
images of tips were averaged and the averages of the
hybrid tip complexes were compared with those of the tip
complexes formed by the LcrV, PcrV and AcrV wt
proteins. Compared with those formed by LcrV, tip com-
plexes formed by PcrV had a smaller base, while both the
neck and the head appeared unchanged (Mueller et al.,
2005) (Fig. 3). In the LcrV–PcrV hybrid protein the
N-terminal globular domain of PcrV was replaced by the
corresponding domain of LcrV, which is 3.2 kDa larger.
This led to a significant increase in the size of the base in
comparison with PcrV tip complexes, while the rest of the
tip complex seemed unchanged (Fig. 3A). Therefore, it
appears that the N-terminal globular domain forms the
base of the tip complex and the central globular domain
the head. Averages of the PcrV–LcrV hybrid protein con-
firmed this hypothesis. Here the N-terminal globular
domain of LcrV was replaced by the smaller domain of
PcrV. As expected, the tip complexes formed by this
hybrid had a smaller base, strongly resembling the base
of tip complexes formed by wt PcrV (Fig. 3A).
Tip complexes formed by AcrV were larger and more
diverse in shape. The base had a different shape, the
neck was less pronounced and the head appeared
broader than in the LcrV tip complex (Mueller et al., 2005).
Compared with LcrV tip complexes, the complexes
formed by the LcrV–AcrV hybrid had a ‘normal’ base, but
the head was larger and of a different shape (Fig. 3B). As
Fig. 3. Tip complexes formed by Y. enterocolitica DHOPEMNV
complemented with the four hybrid proteins. Samples stained with
2% (w/v) sodium phosphotungstate were imaged by dark-field
STEM at a resolution of 1.5 nm.
A. Projection averages of tip complexes formed by wild-type PcrV
[36] and LcrV ([65], top) and the LcrV–PcrV [198], PcrV–LcrV [125]
hybrids (bottom). Schematic representations of all proteins are
drawn next to the corresponding tip complexes.
B. Projection averages of tip complexes formed by wild-type AcrV
[35] and LcrV ([65], top) and the LcrV–AcrV [134], AcrV–LcrV [46]
hybrids (bottom). Schematic representations of all proteins are
drawn next to the corresponding tip complexes.
Projection averages of tip complexes formed by LcrV, PcrV and
AcrV were taken from Mueller et al. (2005). Number in brackets
indicate the number of projections taken to calculate the respective
average. Width of frames is 20 nm.
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the central globular domain of the LcrV–AcrV hybrid is
almost 4 kDa larger than the one of LcrV, this suggests
again that the head is formed by the central globular
domain. The base of the tip complex formed by the last
hybrid, AcrV–LcrV, strongly resembled the base of the
complex formed by wt AcrV (Fig. 3B). All these observa-
tions led to the conclusion that the N-terminal globular
domain of LcrV forms the base of the tip complex, while
the central globular domain forms the head. In addition,
this analysis showed that all the hybrid proteins formed
stable tip complexes; ruling out that instability was the
reason why PcrV–LcrV hybrids were not functional.
Model of the LcrV tip complex
The data presented above, combined with the known
structure of LcrV (Derewenda et al., 2004) and shape and
dimensions of the tip complex (Mueller et al., 2005), indi-
cate that LcrV is oriented with the N- and C-terminus
towards the needle, the N-terminal globular domain
forming the base and the central globular domain the
head of the tip complex. The two long a-helices (a7 and
a12) connect the two globular domains and face inwards.
Attempts were then made to model the tip complex using
the known structure of LcrV in this orientation and the
stoichiometry of 3–5, determined experimentally. The best
fit with the known size of the complex was the pentamer
shown in Fig. 4.
Discussion
The orientation of LrcV in the tip complex, determined
experimentally by STEM measurements, is in perfect
agreement with that proposed by Deane et al. (2006),
based on the assumed best fit between the C-terminal
a-helices of LcrV of Yersinia pestis and MxiH, the needle
subunit of Shigella flexneri. The pentameric stoichiometry
of the tip complex, based on mass-per-length measure-
ments by STEM and on the relative quantification of LcrV
and YscF in purified needles, is also in agreement with the
calculations of Deane et al. (2006). These authors con-
structed an atomic model of the MxiH needle from Shi-
gella and found that they could dock five Yersinia LcrV
molecules onto this structure. More recently, based on
biochemical studies, the same group also suggested a
pentameric structure for the native Shigella needle tip
structure (Veenendaal et al., 2007). However, this pen-
tameric structure would not be a homopolymer but rather
an heteropolymer made of four molecules of IpaD, the
putative orthologue of LcrV, and one molecule of IpaB, the
putative orthologue of YopB (Veenendaal et al., 2007).
Our analysis of the Yersinia system has so far not pro-
vided any conclusive evidence supporting the idea that
the hydrophobic translocators (YopB and YopD) are part
of the tip complex. Although YopD was detected in needle
preparations, it could not be cross-linked to any other
constituent while LcrV could clearly be cross-linked to
YscF, the needle component (Mueller et al., 2005). In
addition, the tip complexes made by Y. enterocolitica
yopB yopD double mutant bacteria were undistinguish-
able from the wt tip complexes (Mueller et al., 2005).
Altogether, this suggests that YopD is not present in
needle preparations because it forms part of the tip
Fig. 4. Side view and top view of the pentameric LcrV tip complex
model at the top of the injectisome needle (represented by two
vertical lines, separated by 8.2 nm). Modelling was performed using
the visualization tool DINO (http://www.dino3d.org), as detailed in
Experimental procedures; the molecular surfaces were calculated
with MSMS (Sanner et al., 1996). In the side view, a single
monomer is highlighted in yellow. In the top view, a colour gradient
has been applied along the chain for aesthetic reasons. Details
available upon request.
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complex but that it rather results from a contamination of
needle preparations by insoluble YopD secreted by Yers-
inia before or during shaving. Hence, we infer that, in
Yersinia, the tip complex is composed of a homopentamer
of LcrV. Whether the tip structure presented in Fig. 4 is
directly connected to the needle, as modelled by Deane
et al. (2006), or whether there is an adapter in between
YscF and LcrV is still unclear and presently under
investigation. For this reason, we did not model the whole
needle end but only the LcrV tip complex.
In the present article, we have also tried to gain some
insight into the function of LcrV and in particular to address
the question of the functional relevance of this character-
istic tip architecture. We took advantage of the fact that
heterologous and hybrid tip proteins form stable com-
plexes on the Yersinia YscF needle and monitored the
functionality of the various tip complexes. Bacteria
endowed with needles ending with PcrV were not func-
tional in an haemolysis assay. This deficiency correlated
with a lack of insertion of YopB into erythrocyte mem-
branes and, interestingly with a lack of interaction between
YopB and PcrV. This result is in good agreement with our
previous observations that LcrV is needed for pore forma-
tion (Goure et al., 2005). However, our present result con-
cerning the insertion of YopB into erythrocyte membranes
is more clear-cut than that presented by Goure et al. In the
latter paper, there was less YopB inserted in the mem-
branes in the absence of LcrV than in its presence. Here
(Fig. 2B) the difference is far more pronounced, because
the experimental conditions were changed to optimize the
haemolysis, which in the present experiment reaches
around 50%, whereas it reached 30% at the best in the
early experiments. The use of the hybrids allowed the
analysis to be refined and showed that it is essentially the
N-terminal globular domain of PcrV that is not functional
with YopB. Even more, the interaction between the tip
complex and YopB is drastically affected when the
N-terminal domain comes from PcrV instead of LcrV or
AcrV. There is thus a good correlation between interaction
of the protein forming the tip complex, the insertion of
YopB into the membrane and formation of a functional
pore. As YopB, like any type III secretion substrate, has to
travel through the narrow channel of the needle, it
emerges in an unfolded configuration. We conclude that
LcrV acts as some kind of an assembly platform for YopB
and that the N-terminal globular domain, forming the base
of the tip structure, is key for this activity. We therefore
propose that LcrV is the archetype of a new group of
extracellular scaffold proteins dedicated to the proper
folding of hydrophobic pore formers. The idea that
unfolded hydrophobic proteins do not insert spontane-
ously into membranes is not new and several examples
have emerged recently. One of the most striking is the
discovery of Omp85/YaeT, as an ‘assembly factor’ for
Neisseria/E. coli outer membrane proteins emerging from
the sec machinery (Voulhoux et al., 2003; Doerrler and
Raetz, 2005; Sklar et al., 2007). Following the observation
that Omp85 recognizes its substrate by a C-terminal con-
served domain (Robert et al., 2006), it will be interesting to
determine how LcrV recognizes YopB. Another point that
remains to be clarified is whether LcrV also acts as an
assembly factor for YopD. The binding experiments
suggest a positive answer. Although YopD does not need
LcrV to become associated with membranes, its proper
insertion could still depend on LcrV. Finally, the structure of
the translocation pore still needs to be elucidated. Once
this is achieved, it will be possible to model the connection
between tip complex and pore.
Experimental procedures
Bacterial strains, oligonucleotides and plasmids used
this study
This study was carried out with Y. enterocolitica E40 carrying
several mutations on the virulence pYV plasmid, listed in
Table 1.
Oligonucleotides used for the genetic constructions are
listed in Table S1.
Hybrids between lcrV, pcrV or acrV were generated using
overlapping PCR. Individual parts of every hybrid were ampli-
fied from the corresponding DNA sequences by PCR with the
primer pairs as indicated in Fig. S2A. The PCR products
(fragments 1 and 2) were mixed and served as template for the
overlapping PCR, which was performed using the appropriate
primers (Fig. S2A). The PCR product was digested with NcoI/
EcoRI or AflIII/EcoRI and cloned into the NcoI/EcoRI sites of
the expression vector pBADmycHisA (Invitrogen) giving plas-
mids pPB30, pPB31, pPB34 and pPB35. To generate His-
tagged LcrV, PcrV,AcrV and hybrids, the genes were amplified
from the corresponding plasmids by PCR. The sequence of
the forward primers included the 6-His-tag (Table S1). The
PCR product was digested with NcoI/EcoRI orAflIII/EcoRI and
cloned into the NcoI/EcoRI sites of the expression vector
pBADmycHisA (Invitrogen) giving plasmids pPB58-64.
Growth conditions
Bacteria were routinely grown on Luria–Bertani agar plates
and in liquid Luria–Bertani medium. Ampicillin was used at a
concentration of 200 mg ml-1 to select for the expression plas-
mids. For the induction of the yop regulon, Y. enterocolitica
bacteria were inoculated to an OD600 of 0.1 and cultivated in
brain–heart infusion (BHI; Remel) supplemented with a
carbon source, 20 mM MgCl2 and 20 mM sodium oxalate
(BHI-Ox) for 2 h at 25°C, then shifted to 37°C and incubated for
4 h (Cornelis et al., 1987; Agrain et al., 2005). Expression of
the different genes cloned downstream the pBAD promoter
was induced by adding 0.2% arabinose to the culture just
before the shift to 37°C, and again 2 h later. The carbon source
was glycerol (4 mg ml-1) when expressing genes from the
pBAD promoter, and glucose (4 mg ml-1) in the other cases.
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For every culture that was used for needle preparation, the
secreted Yop proteins were analysed by SDS-PAGE. Secreted
proteins were precipitated for 1 h at 4°C with trichloroacetic
acid 10% (w/v) final and separated by SDS-PAGE. Proteins
secreted by 3 ¥ 108 bacteria were loaded per lane. After
electrophoresis, proteins were stained with Coomassie bril-
liant blue (Pierce) or transferred to nitrocellulose membranes.
Immunoblotting and far-Western blots
Immunoblotting was carried out using rabbit polyclonal anti-
bodies directed against YscF (MIPA80) or LcrV (MIPA220),
rat monoclonal antibodies directed against YopB (MIPA98) or
YopD (MIPA96) or a commercial antibody directed against
the 6-His-tag (GE Healthcare). Detection was performed with
secondary antibodies conjugated to horseradish peroxidase
(1: 2000; Dako) before development with supersignal chemi-
luminescent substrate (Pierce).
For the far-Western blots, Y. enterocolitica bacteria were
grown in secreting conditions (see above), and secreted pro-
teins were precipitated for 1 h at 4°C with trichloroacetic acid
10% (w/v) final, separated by SDS-PAGE and transferred to
nitrocellulose membranes. The membranes were blocked
with BSA in PBS-Tween (0.1% Tween, 0.1% BSA), incubated
with equimolar amounts of the purified, His-tagged proteins
for 2 h at room temperature and washed extensively with
PBS. The membranes were probed with anti-His antibodies
to reveal where the protein bound.
Production and purification of recombinant protein
Soluble LcrV protein was produced in E. coli BL21 (DE3)
pLysS expressing His-LcrV from plasmid pPB10 (Table 1).
Bacteria were grown at 37°C to an OD600 of 0.6 and the
expression was induced by the addition of 0.1 mM isopropyl-
b-D-thiogalactopyranoside for 4 h at 37°C. The bacteria were
lysed by three passes in a French pressure cell and the
recombinant protein was purified on chelating sepharose
beads (Amersham Biosciences).
YscF was produced as described before (Mueller et al.,
2005).
LcrV, AcrV, PrcV and hybrid proteins used for the far-
Western blotting were produced by E. coli TOP10 bacteria
(Invitrogen), using plasmids pPB58 to pPB64 (Table 1). Bac-
teria were grown at 37°C to an OD600 of 0.6 and the expres-
sion was induced by the addition of 0.1% arabinose for 4 h at
37°C. Bacteria were lysed by passages in a French pressure
cell and the recombinant protein was purified on chelating
sepharose beads (Amersham Biosciences).
Haemolysis assays and RBC membrane isolation
Haemolysis assays and RBC membrane isolation were
carried out using an improved protocol, based on the assay
described by Goure et al. (2005), which increases the efficacy
of the haemolysis with Yersinia. Briefly, RBCs were
re-suspended in Tris-saline [30 mM Tris and 150 mM
Table 1. Plasmids used in this study.
Plasmid Current designation Relevant characteristics References
pYV plasmids
pYV40 wt pYV plasmid of Y. enterocolitica E40 Sory et al. (1995)
pMN4002 DHOPEMNV pYV40 yopE21 yopHD1–352yopOD65–558
yopP23yopM23yopN45lcrVD6–319
Marenne et al. (2003)
pMN4003 DHOPEMNVQ pYV40 yopE21 yopHD1-352yopOD65-558
yopP23yopM23yopN45lcrVD6-319yopQ17
Marenne et al. (2003)
pIM417 DHOPEMN pYV40 yopE21 yopHD1-352yopOD65-558 yopP23yopM23yopN45 Neyt and Cornelis (1999)
pSIL4009 DYscP pYV40yscPD97–465 Stainier et al. (2000)
Vectors and clones
pBAD/MycHisA Invitrogen
pET28a Novagen
pGEX4T3 Amersham
pCA1 pBAD/MycHisA-yscP +D1–15 Agrain et al. (2005)
pISO66 pGEX4T3-yscF + Mueller et al. (2005)
pMN12 pBBR1MCS-2 pyopElcrV + Marenne et al. (2003)
pPB10 pET28a-lcrV + Mueller et al. (2005)
pPB24 pBAD/MycHisA-pcrV + Mueller et al. (2005)
pPB25 pBAD/MycHisA-acrV + Mueller et al. (2005)
pPB30 pBAD/MycHisA-lcrV-pcrV + This work
pPB31 pBAD/MycHisA-pcrV-lcrV + This work
pPB34 pBAD/MycHisA-lcrV-acrV + This work
pPB35 pBAD/MycHisA-acrV-lcrV + This work
pPB42 pBAD/MycHisA-lcrV + This work
pPB58 pBAD/MycHisA-his-lcrV + This work
pPB59 pBAD/MycHisA-his-pcrV + This work
pPB60 pBAD/MycHisA-his-acrV + This work
pPB61 pBAD/MycHisA-his-lcrV-pcrV + This work
pPB62 pBAD/MycHisA-his-pcrV-lcrV + This work
pPB63 pBAD/MycHisA-his-lcrV-acrV + This work
pPB64 pBAD/MycHisA-his-acrV-lcrV + This work
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NaCl (pH 7.5)] at 1 ¥ 1010 cells ml-1. For the infection
Y. enterocolitica bacteria were inoculated to an OD600 of 0.1
and cultivated in BHI (Remel) at 37°C for a total of 3 h.
Expression of the different genes cloned downstream of the
pBAD promoter was induced by adding 0.2% arabinose after
1 h. Defined amounts of bacterial culture [multiplicity of infec-
tion (moi) = 1] were transferred into 50 ml conical tubes
(Falcon) and the bacteria were pelleted by centrifugation
(5 min, 3220 g). The supernatant was removed and the bac-
terial pellet was re-suspended in 2 ml of a 3:1 mix of Tris-
buffer:BHI containing the appropriate amount of RBCs and
protease inhibitor cocktail (Complete-mini, Roche). The infec-
tion assay was centrifuged (10 min, 1000 g, 37°C, swing-out
rotor) and incubated for 2 h at 37°C. The RBC bacteria pellet
was re-suspended by vortexing and pelleted again (10 min,
1000 g, 4°C, swing-out rotor). Samples were taken from the
supernatant to determine the level of haemolysis and protein
content of the infection supernatant. Then, 4 ml of ice-cold
distilled water was added to lyse the RBCs, and the mixture
was centrifuged again to pellet the bacteria (10 min, 3220 g,
4°C). The RBC membranes were isolated by floatation on a
sucrose gradient as described previously (Goure et al., 2004).
The membranes were collected, washed with Tris-saline to
remove the sucrose and prepared for SDS-PAGE analysis.
STEM mass measurements of needles
The needles were purified as described previously (Mueller
et al., 2005), diluted in buffer (20 mM Tris-HCl, pH 7.5) as
required and adsorbed to thin carbon film coated grids. After
washing on four droplets of quartz double-distilled water, the
grids were freeze-dried at -80°C and 5 ¥ 10-8 Torr overnight in
the microscope. The STEM was operated at an acceleration
voltage of 80 kV. Digital images were recorded at a nominal
magnification of 200 000¥ using doses of 480  107 electron-
s nm-2. Tobacco mosaic virus (TMV, kindly supplied by Dr R.
Diaz-Avalos, Institute of Molecular Biophysics, Florida State
University) was adsorbed to separate grids and served as a
mass standard. The digital images were evaluated using the
program package MASDET (V. Krzyzanek, S.A. Müller, A. Engel
and R. Reichelt, in preparation), a refined version of IMPSYS
(Müller et al., 1992). The results were corrected for beam-
induced mass loss according to previous measurements
made on extra-long needles produced by yscP mutant bacte-
ria [E40(pSIL4009)] expressing pCA1 (data not shown), and
scaled to the mass of TMV, binned, displayed in a histogram
and described by a Gaussian curve.
Imaging and averaging of tip structures
The purified needles were diluted with buffer (20 mM Tris-HCl,
pH 7.5) as required, adsorbed to thin carbon film, washed on
four droplets of quartz double-distilled water and stained with
2% (w/v) sodium phosphotungstate. To calculate the averages
of the tip complexes, subframes were manually selected from
the STEM dark-field images recorded at a nominal magnifica-
tion of 500 000¥ and angularly and translationally aligned to an
arbitrary reference using the SEMPER program package
(Saxton et al., 1979; Saxton and Baumeister, 1982). First
averages calculated from 50–200 aligned subframes were
twofold symmetrized along the cylinder axis and used to
calculate a refined average. Those subframes that had a
cross-correlation value > 0.65 were included in the final
average. A twofold symmetry was then applied. The resolution
was determined from the Fourier ring correlation function of
the independent averages calculated from the odd- and even-
numbered subframes applying the 0.5 criterion.
Modelling of the tip complex
Modelling was based on the atomic co-ordinates of the LcrV
monomer, determined by X-ray crystallography (PDB code
1R6F, Derewenda et al., 2004). For this purpose, the visual-
ization tool DINO (http://www.dino3d.org) was employed,
which allows the display of circular symmetry mates as well
as their synchronous real-time update upon transformation of
the reference monomer. Constrains applied during the mod-
elling procedure were: (i) circular symmetry corresponding to
a pentameric structure (fivefold symmetry around the z-axis),
(ii) shape corresponding to averaged EM density, (iii) hollow
interior to accommodate the channel, (iv) epitope region
(residues 135–275) oriented towards the outside, (v) con-
served residues between LcrV, PcrV and AcrV oriented
towards the interior and (vi) packing between monomers
without steric clashes.
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Fig. S1 A. Atomic structure of the LcrV protein from Y. pestis (Derewenda et al, 2004). B. 
Sequence alignment of AcrV from A. salmonicida, LcrV from Y. enterocolitica and PcrV from P. 
aeruginosa using Multalin (www.expasy.ch). The two helices (α7 and α12 in LcrV) that connect 
the globular domains of the proteins are marked in gray, red: high consensus, blue: low 
consensus. The black arrows indicate the end of the first globular domain of the V-antigen, 
which was swapped in the hybrid proteins. 
 A 
PCR1 PCR2 Overlaping PCR 
Fragment 1 Primers Template Fragment 2 Primers Template Hybrid Primers Templates 
LcrV 1-145 3934 3806 pMN12 PcrV 124-294 
3935 
3809 pPB24 LcrV-PcrV 
3806 
3809 
LcrV 1-145 
PcrV 124-294 
PcrV 1-123 3937 3957 pPB24 LcrV 146-324 
3936 
3807 pMN12 PcrV-LcrV 
3957 
3807 
PcrV 1-123 
LcrV 146-324 
LcrV 1-145 3942 3806 pMN12 AcrV 146-361 
3943 
3811 pPB25 LcrV-AcrV 
3806 
3811 
LcrV 1-145 
AcrV 146-361 
AcrV 1-143 3945 3810 pPB25 
 
LcrV 146-324 3944 3807 pMN12 
 
AcrV-LcrV 3810 3807 
AcrV 1-143 
LcrV 146-324 
 
 
B 
 
Protein aa LcrV aa PcrV aa AcrV Size (kDa) 
LcrV 1-324   37.6 
PcrV  1-294  32.2 
AcrV   1-361 40.2 
LcrV-PcrV 1-145 124-294  35.6 
PcrV-LcrV 146-324 1-123  34.3 
LcrV-AcrV 1-145  146-361 41.5 
AcrV-LcrV 146-324  1-143 36.2 
 
 
 
 
 
 
 
Fig. S2 Cloning of the hybrid proteins A. Table listing the primers and templates that were used 
to generate the individual fragments of lcrV, pcrV and acrV, as well as the primers and 
templates used in the overlapping PCR reaction to generate the hybrids. The region spanned by 
the PCR fragments is indicated in amino acids of the respective protein. B. Schematic 
representation of LcrV, PcrV, AcrV and the hybrid proteins. The length, amino acid composition 
and size of every protein is indicated. 
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Fig S3 Far-western blots, demonstrating the interaction of LcrV, PcrV, AcrV and the four hybrid 
proteins with the translocators YopB and YopD and the needle subunit YscF. Culture 
supernatant from Y. enterocolitica ∆HOPEMN (lane 1) ∆HOPEMNV (lane 2), grown in 
secretion-permissive conditions, was separated by SDS-PAGE, blotted on nitrocellulose 
membranes and incubated with purified, His-tagged proteins. Blots were developed with anti-
His antibodies to reveal where the protein bound. Bands corresponding to YopB, YopD, LcrV 
and YscF are indicated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S1 Oligonucleotides used in this study 
 
 
Codes  Oligonucleotides  Underlined 
sites 
   
3806 ATCATGCCATGGCAATTAGAGCCTACGAACAAAACC NcoI 
3807 CCGGGCGAATTCTTACCTCGTGTCATCTAGCAG EcoRI 
3809 CCGGGCGAATTCCTAGATCGCGCTGAGAATGTC EcoRI  
3810 TGCCCACATGTCAAGCACAATCCCTGACTACAAC AflIII  
3811 CCGGGCGAATTCTCAAATTGCGCCAAGAATGTC EcoRI  
3934 CCTTGCGCTTGCCGTCCTGATGATTCATTGAATCAACAATCACT  
3935 AGTGATTGTTGATTCAATGAATCATCAGGACGGCAAGCGCAAGG  
3936 CTACAAGGATGTCCTGCAGACCCATGGTGATGCCCGTGGCAAG  
3937 CTTGCCACGGGCATCACCATGGGTCTGCAGGACATCCTTGTAG  
3942 CCCTTTACGCTGATTGTCCTGATGATTCATTGAATCAACAATCACT  
3943 AGTGATTGTTGATTCAATGAATCATCAGGACAATCAGCGTAAAGGG  
3944 CCTTTACCGGGGTGATGATGTTTCATGGTGATGCCCGTGGCAAG  
3945 CTTGCCACGGGCATCACCATGAAACATCATCACCCCGGTAAAGG  
3957 TGCCCACATGTCAGAAGTCAGAAACCTTAAGTCC AflIII 
4341 TGCCCACATGTCACATCATCATCATCATCATCAGGGCGCCATGAGCA
CAATCCCTGACTACAAC 
AflIII 
4342 ATCATGCCATGGCACATCATCATCATCATCATCAGGGCGCCATGATT
AGAGCCTACGAACAAAACC 
NcoI 
4343 TGCCCACATGTCACATCATCATCATCATCATCAGGGCGCAATGGAAG
TCAGAAACCTTAATGCC 
AflIII 
4344 ATCATGCCATGGCACATCATCATCATCATCATCAGGGCGCAATGGAA
GTCAGAAACCTTAATGCC 
NcoI 
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3.3 Crosslinking and nanogold labeling of the tip complex
Cystein specific crosslinking and nanogold labeling are powerful tools for the
analysis of protein complexes. Homobifunctional cystein crosslinkers
specifically react with cysteins within a protein or between proteins.
Nanogold are small gold cluster with a diameter of 1.4 nm, which are linked to a
reactive functional group. Monomaleimido Nanogold® is a gold particle linked to
a single monomaleimid functional group that specifically reacts with cysteins in
a protein.
The aim of the crosslinking and nanogold labeling experiments was to
determine the stoichiometry and orientation of LcrV in the tip complex.
3.3.1 Mutation of the cystein at postion 278 in LcrV to serine
The cystein at position 278 in LcrV was mutated to serine (LcrVC278S), to get a
cystein free variant of LcrV, which can be used as a background for site-specific
insertion of cysteins for crosslinking and nanogold experiments. LcrVC278S was
cloned into the pBAD vector under the control of the arabinose promoter
(pCAM17).
Needles purified from the ∆HOPEMNVQ strain complemented with pCAM17
(LcrVC278S) had wild type tip complexes and were functional in the hemolysis
assay (data not shown).
3.3.1 Cystein specific crosslinking of LcrV
To determine the stoichimetry of LcrV in the tip complex, several different LcrV
variants containing two cysteins were constructed in the LcrVC278S background
(pCAM17). Based on the pentameric tip complex model (Broz et al., 2007), the
two cysteins were placed to allow inter-molecular, but minimize intra-molecular
crosslinking events (Figure 11). To avoid disruption of the overall LcrV
structure, except in one case (pCAMP35), all the cysteins were placed in loops
or unstructured regions of the protein (Figure 12).
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Figure 11: Sequence of LcrV from Y. enterocolitica MRS40. Residues exchanged by cysteins
for crosslinking are marked with different colours.
All of the generated LcrV variants were tested for their ability to complement an
lcrV mutant both in secretion and hemolysis experiments.
The LcrV variant in which the cysteins were inserted into a helix region of the
protein (pCAMP35) did not complement the lcrV mutant (∆HOPEMNVQ).
Secretion of LcrV and levels of hemolysis were comparable to wild type for all
the other constructs in the lcrV mutant (∆HOPEMNVQ) (data not shown).
Three cystein specific homobifunctional crosslinkers with different spacer arm
lengths (Figure 13) were used to crosslink the tip complex of needles purified
from the ∆HOPEMNVQ strain complemented with the different cystein variants
of LcrV. As a control, needles purified from the ∆HOPEMTasd strain (wild type
LcrV, one cystein) were crosslinked under the same conditions.
Western blots of the crosslinked needles using the anti-LcrV antibody revealed
several high molecular weight products. These were absent in the non-
crosslinked sample. However, even though it must be assumed that the
stoichiometry of LcrV in the tip complex remained unchanged, the pattern of
crosslink products was different for each of the LcrV variants. In addition
crosslinking of needles from the ∆HOPEMTasd strain in which LcrV only
contains the native cystein also lead to the appearance of high molecular
weight bands detectable by the anti-LcrV antibody. This strongly suggests that
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the crosslinking was unspecific, since significant crosslinking products would
not be expected in the case of wt LcrV (∆HOPEMTasd) (data not shown).
Figure 12: Model of the tip complex formed by 5 LcrV displayed by RasMol v2.6. The positions
of the two cysteins introduced into LcrV are marked in blue and red.
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The buffer used for needle purification (20 mM Tris HCl pH 7.5) is not ideal for
crosslinking and can interfere with the reaction. It is therefore possible that the
crosslinkers used were less specific and reacted with primary amines, leading
to intra-molecular LcrV crosslinking and crosslinking to the YscF needle. There
are no cysteins in YscF but about 9% of the LcrV and YscF amino acids are
lysines, which could explain the unspecific crosslinking patterns observed.
Figure 13: A) Homobifuctional cystein crosslinkers used to determine the stoichiometry of LcrV
in the tip complex. B ) Schematic representation of the crosslinking reaction (taken from
www.piercenet.com). The sphere represents a protein containing sufhydryl groups.
The crosslinking experiments were finally abandoned and the stoichiometry of
LcrV in the tip complex was estimated to be 4 +/- 1 by combining the results
from STEM mass-per-length measurements of purified needles and quantitative
immuno-blots (Broz et al., 2007).
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3.3.2 Nanogold® labeling of LcrV
The crystal structure of LcrV can be fitted into the average electron density map
of the tip complex obtained by STEM (Mueller et al., 2005) in two different
orientations, either with the N-terminal globular domain forming the base, or the
head of the tip complex.
A cystein was inserted into LcrV as first amino acid at the N-teminus, last amino
acid at the C-terminus or in a loop region at amino acid position 227, for
nanogold labeling and STEM analysis to determine the orientation of LcrV in the
tip complex (Table 2).
Construct Position of inserted cystein
pCAMP18 C-terminus, before stop
pCAMP19 N-terminus, after start
pCAMP22 Between amino acids 227 and 228 in a variable loop
Table 2: Insertion of Cysteins for nanogold labeling into LcrVC278S (pCAM17)
All three generated LcrV variants complemented an l c rV  mutant
(∆HOPEMNVQ) both in secretion and hemolysis experiments (data not shown).
Phospho-tungstic acid (PTA) negative staining was routinely used to analyze
purified needles by STEM. This is not the ideal staining solution for the
detection of nanogold particles attached to protein complexes, since it makes
detection of the gold particles difficult. NanovanTM, the negative stain suggested
for use with nanogold, was tested for visualization of the tip complex of wild
type needles by STEM. The tip complex was clearly visible and the central
channel of the needle and tip complex became more apparent than for needles
stained with PTA, probably due to better stain penetration (Figure 14).
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Figure 14: A) Wild type needles stained with Nanovan™. B) Wild type needles stained with 2%
phosphotungstic acid (PTA)
Need les  we re  pu r i f i ed  f r om ∆HOPEMNVQ+pCAMP19 ,
∆HOPEMNVQ+pCAMP22 and ∆HOPEMTasd and the amount of LcrV in the
purified needle fraction was estimated to be around 20 ng/µl by Western
Blotting using known amounts of purified His-LcrV and a polyclonal anti-LcrV
antibody (data not shown).
Labeling was attempted using up to 66-fold excess of nanogold compared to
LcrV and various incubation times.
Labeled samples were re-suspended in non-reducing SDS-PAGE sample
buffer, not boiled, run on SDS-PAGE and blotted to nicrocellulose membranes.
Immunoblotting revealed a broad smear of protein detected by the polyclonal
anti-LcrV antibodies ranging from about 36 to 50 kDa. This indicates that either
labeling of LcrV did occur, or that the non-reducing sample buffer did not fully
unfold LcrV. The membranes were subsequently developed using
GoldEnhaceTM, which allows direct visualization of gold on the membranes. For
most conditions tested a faint band was detected at about 50 kDa and that
could correspond to LcrV labeled with nanogold (data not shown).
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Unfortunately after incubation with nanogold, the needles were not detectable
by STEM, even though YscF and LcrV were readily detected by Western
Blotting (data not shown).
Another problem with the gold labelling experiments was that the needles stick
to various surfaces, such as filter membranes, gelfiltration matrices and latex
beads. Therefore the excess of unbound gold particles could not be removed
and labelled needles could not be concentrated or separated from unlabelled
ones.
Due to the problems to visualize the labeled needles by STEM it was not
possible to determine the orientation of LcrV in the tip complex using this
approach. Analysis of hybrids between LcrV/PcrV and LcrV/AcrV finally allowed
the orientation of LcrV in the tip complex to be defined (Broz et al., 2007).
Materials and Methods
Construction of plasmids
The cystein at amino acid position 278 in LcrV was replaced using overlapping PCR and the
pYV40 as a template. The PCR product was digested with NcoI/EcoRI and cloned into the
NcoI/EcoRI sites of the expression vector pBAD/mycHisA (Invitrogen) giving plasmid pCAM17.
The different cysteins for crosslinking and nanogold labeling were insertd into LcrV by
overlapping PCR using pCAM17 as a template. The PCR products were digested with
NcoI/EcoRI and cloned into the NcoI/EcoRI sites of the expression vector pBAD/mycHisA
(Invitrogen).
The cysteins for the crosslinking were added one by one giving rise to intermediate plasmids
containing LcrV with one added cystein (pCAMP30, pCAMP32, pCAMP34, pCAMP36,
pCAMP38) ehich was subsequently used to generate LcrV containing two cysteins (pCAMP31,
pCAMP33, pCAMP35, pCAMP37, pCAMP39).
The cysteins for the nanogold experiments were inserted into LcrV in one step, giving rise to
plasmids pCAM18, pCAM19, pCAM22 (Table 3).
Name Description Vector Selection Oligos used
pCAM17 lcrVC278S pBAD/mycHisA Amp 3806, 3807, 4252, 4253
pCAM18 lcrVC278S, 330C pBAD/mycHisA Amp 3806, 4263
pCAM19 lcrV2C, C278S pBAD/mycHisA Amp 3807, 4267
pCAM22 lcrV228C, C278S pBAD/mycHisA Amp 3806, 3807, 4335, 4336
pCAMP30 LcrVC278S, S282C pBAD/mycHisA Amp 3806, 3807, 4498, 4499
pCAMP31 LcrVN232C, C278S, S282C pBAD/mycHisA Amp 3806, 3807, 4500, 4501
pCAMP32 LcrVD133C, C278S pBAD/mycHisA Amp 3806, 3807, 4502, 4503
pCAMP33 LcrVD133C, D203C, C278S pBAD/mycHisA Amp 3806, 3807, 4504, 4505
pCAMP34 LcrVH89C, C278S pBAD/mycHisA Amp 3806, 3807, 4506, 4507
pCAMP35 LcrVH89C, A209C, C278S pBAD/mycHisA Amp 3806, 3807, 4508, 4509
pCAMP36 LcrVC278S, D287C pBAD/mycHisA Amp 3806, 3807, 4510, 4511
pCAMP37 LcrVG233C, C278S, D287C pBAD/mycHisA Amp 3806, 3807, 4512, 4513
pCAMP38 LcrVN96C, C278S pBAD/mycHisA Amp 3806, 3807, 4514, 4515
pCAMP39 LcrVN96C, E205C, C278S pBAD/mycHisA Amp 3806, 3807, 4516, 4517
Table 3: LcrV constructs for crosslinking and nanogold labeling
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Complementation of ∆HOPEMNVQ
Secretion and hemolysis experiments to test complementation of the ∆HOPEMNVQ strain
(MIPA 1519) with the different LcrV constructs, were done as described before (Goure et al.,
2005; Mueller et al., 2005)
Needle purification and STEM
Needle purification and STEM analysis was done as described before (Mueller et al., 2005),
except that for gold labeled samples NanovanTM (www.nanoprobes.com) was used as negative
staining solution instead of PTA (Mueller et al., 2005).
Immunoblotting
Immunoblotting was carried out using rabbit polyclonal antibodies directed against LcrV (MIPA
220). Detection was performed with secondary antibodies conjugated to horseradish peroxidase
(1:2000; Dako) before development with supersignal chemiluminescent substrate (Pierce).
Crosslinking experiments
The crosslinkers BMH, BM(PEO)2 and BM(PEO)3 (Pierce) were dissolved in DMSO according
to the suppliers protocol (www.piercenet.com). Purified needles were incubated with a final
concentration of 2 mM crosslinker for different times at room temperature and the reaction was
quenched by the addition of 100 mM DTT and re-suspended in SDS-PAGE sample buffer for
immunoblotting. As a control needles were subjected to the same treatment but in the absence
of crosslinker.
Nanogold labeling
LcrV in purified needles was roughly quantified using purified His-LcrV and Western blotting
using the polyclonal anti-LcrV antibody.
The Nanogold® (www.nanoprobes.com) was reconstituted in 10 % isopropanol in water and
vortexed. Purified needles were incubated with different amounts of gold solution (up to 66 fold
excess of gold) for different times at room temperature, or at room temperature for 1 hour
followed by incubation at 4°C over night. The samples were then either prepared for analysis by
STEM or resuspended in non-reducing SDS-PAGE sample buffer for immunoblotting and
GoldEnhanceTM detection.
After detection by immunoblotting GoldEnhanceTM reagent (www.nanoprobes.com) was added
to the nitrocellulose membrane according to the suppliers protocol for nanogold detection.
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3.4 Purification of the translocation pore
Several attempts to purify the type III sescretion translocation pore have been
made in the past (Ide et al., 2001; Schoehn et al., 2003). In these studies the
pore was never isolated from the host cell membrane after insertion by live
bacteria. Using His-tagged variants of YopB and YopD an attempt was made to
purify the translocation pore from isolated red blood cell membranes after
hemolysis induced by Yersinia enterocolitica.
3.4.1 Construction of yopD mutants
The yopD gene in MRS40 wt and ∆HOPEMN was deleted by allelic exchange
(Marenne et al., 2003) using the mutator pCAM8. yopD is the last gene in the
translocator operon and has a size of 921 bp (307 aa).
YopD was not detectable in the supernatant of the generated ∆yopD
(pCAM4001) and ∆HOPEMND (pCAM4002) strains after secretion; secretion of
YopB, LcrV and the other Yops was not affected. Complementation of the yopD
mutants with a plasmid encoding yopD under the control of the arabinose
promoter (pPB6), lead to secretion of YopD, but the amount of exported YopD
was reduced compared to wild type possibly due to expression from the
plasmid (Figure 15).
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Figure 15: Complementation of the ∆yopD and ∆HOPEMND mutants (pCAM4001 and
pCAM4002, respectively). A) Coomassie stained SDS-PAGE of the secretion supernatant,
bands corresponding to YopD secreted by the complemented (pPB6) mutants are marked with
an arrowhead. B) Anti-YopB and anti-YopD Western blots of the secretion supernatant.
In addition, the ability of the ∆HOPEMND strain to induce hemolysis of RBC
was tested. As expected the mutant did not lead to RBC lysis, whereas
complementation of the mutant with yopD in trans (pPB6) restored hemolysis to
wild type levels (data not shown).
3.4.2 Construction and analysis of different His-YopB and His-YopD variants
A His6-tag directly linked to the N-terminus of YopB (pPB2) or YopD (pPB5) was
previously tested for purification of the translocation pore using Ni2+-columns,
however the His-tagged proteins either not bound to the Ni2+-column very
inefficiently or not at all (Nadine Schracke and Catherine Mueller, unpublished).
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To increase the accessibility of the His-tag to the matrix of the column, different
His-tags lengths, and different spacers between the His-tag and the N-teminus
of YopB and YopD were added to the proteins. In addition YopB was tagged
with the HAT-tag, which is a naturally occurring sequence of 14 amino acids
with 6 irregularly distributed histidines along the sequence (HAT sequence:
KDHLIHNVHKEFHAHAHNK; Table 4)
Construct Tagged protein Tag Spacer between tag and YopB/YopD
pCAM62 YopB His10 none
pCAM63 YopB His6 5 aa (G-G-A-G-G)
pCAM65 YopB HAT none
pCAM66 YopD His10 none
pCAM67 YopD His6 5 aa (G-G-A-G-G)
pCAM68 YopD His6 10 aa (G-G-A-G-G-A-G-G-A-G)
Table 4: His-YopB, HAT-YopB and His-YopD constructs for purification of the translocation
pore
All of the YopB (Figure 16) and YopD (Figure 17) variants generated were able
to complement the ∆HOPEMNB or ∆HOPEMND strain. However, the levels of
hemolysis and amounts of YopB and YopD secreted or inserted into RBC
membranes were somewhat reduced compared to the ∆HOPEMN strain (wild
type YopB/YopD; Figure 16, Figure 17).
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Figure 16: Complementation of the ∆HOPEMNB strain with the His-YopB and HAT-YopB
constructs. pCAM62: His10-yopB, pCAM63: His6-G-G-A-G-G-YopB,
pCAM65: HAT-YopB. A) Hemolysis assay. B) Anti-YopB and anti-YopD Western blots of
secretion supernatant. C) Anti-YopB and anti-YopD Western blots of isolated red blood cell
membranes after hemolysis.
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Figure 17: Complementation of the ∆HOPEMND strain with the His-YopD constructs. pCAM66:
His10-YopD, pCAM67: His6-G-G-A-G-G-YopD, pCAM68: His6-G-G-A-G-G-A-G-G-A-G-YopD A)
Hemolysis assay. B) Anti-YopB and anti-YopD Western blots of secretion supernatant. C) Anti-
YopB and anti-YopD Western blots of isolated red blood cell membranes after hemolysis.
Results
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3.4.3 Purification of the translocation pore using His6- (G-G-A-G-G)-YopD
(pCAM67)
Hemolysis assays followed by RBC membrane isolation were performed using
the ∆HOPEMND strain complemented with the His6-(G-G-A-G-G)-YopD variant
(pCAM67).
Isolated membranes were solubilised with 1% Triton X-100 and purification of
the pore was attempted using Ni2+-columns.
Most of the protein detectable by the anti-YopD antibody was found in the flow
through fractions (fractions 1-5) of the columns, indicating that either the protein
had not bound to the columns or that the columns were saturated with
contaminating proteins such as hemoglobin (Figure 18). YopD was also
detected in early elution fractions (fractions 15-17), however these fractions did
not correspond to the small peak observed in the A280 absorption curve,
indicating that the amount of YopD in these fractions was below the detection
limit of A280 absorption (Figure 18). Furhter, YopD was also detected in later
elution fractions (fractions 28-36) at full imidazol concentration in the elution
buffer (500mM imidazol). The elution fractions containing YopD were also
analyzed by silver stained SDS-PAGE and were found to contain many
contaminating proteins (data not shown). YopB was only detected in the flow
through fractions of the columns, never in the elution fractions together with
YopD. This indicates that the interaction between YopD and YopB was not
strong enough to persist during the purification process. Crosslinking
approaches could help to solve this problem.
Since most of the tagged YopD was lost in the flow through of the columns, it is
possible that the five amino acid spacer between the His-tag and YopD was not
long enough to get sufficient exposure of the His-tag for efficient binding of
YopD to the Ni2+-columns. In the future, the binding of the other YopD variants
and the functional His-YopB constructs will need to be tested. Using Ni2+-
columns in this way will allow a first step of purification of the translocation pore,
which can then be followed by additional purification steps such as gelfiltration.
Results
49
So far the results obtained with this His-tagged construct (pCAM67) have not
been very reproducible. The only thing that was consistently observed was the
loss of YopD and YopB in the flow through fractions of the Ni2+-columns.
Figure 18: A) Representative elution profile of the Ni2+-columns of the pore purification using
∆HOPEMND+pCAM67, fractions containing YopD are marked in yellow. Blue line A280, green
line concentration of buffer B containing 500 mM imidazole. B) Anti-YopD Western blots of the
elution fractions.
Results
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Materials and Methods
Deletion of yopD
To delete the yopD gene, yopB and the 214 bp after the yopD gene were fused by overlapping
PCR and cloned into the SalI/XbaI sites of pBlusecript KS+II (Stratagene) giving plasmid
pCAM3. A fragment containing the last 244 bp of yopB and the 214 bp after yopD was amplified
by PCR and cloned into the SalI/XbaI sites of pMRS101 giving rise to plasmid pCAM7. pCAM7
was digested with NotI to excise the ampicillin resistance marker and the oriE1 and re-ligated
resulting in the mutator pCAM8. The yopD gene on the Y. enterocolitica MRS40 wt and
∆HOPEMN pYV plasmid was deleted by allelic exchange with pCAM8 as described previously
(Marenne et al., 2003). The resulting Y. enterocolitica mutant pYV plasmids were called
pCAM4001 (∆yopD, MIPA 2091) and pCAM4002 (∆HOPEMND, MIPA 2092) (Table 5).
Construction of plasmids
His-tags and spacers were added to YopB and YopD by PCR, using oligos containing the tag
and spacer sequence. The pYV40 was used as a template for amplification of yopB. yopD
contains an NcoI site that was mutated (pISO81) and used as a template for the amplification of
yopD. The PCR products were digested with NcoI/EcoRI and cloned into the NcoI/EcoRI sites
of the expression vector pBAD/HisB (Invitrogen) giving different plasmids containing His-tagged
YopB (pCAM62, pCAM63), a HAT tagged version of YopB (pCAM65) and His-tagged YopD
(pCAM66, pCAM67, pCAM68; Table 5).
pYV plasmids
Name Description
pCAM4001 pYV40 yopD
pCAM4002 pYV40 yopE21 yopH∆1–352 yopO∆65–558 yopP23 yopM23 yopN45 yopD
Clones
Name Description Vector Selection Oligos used
pCAM3 y o p B , 214bp after
yopD
pBluscript
KS+II
Amp 3858, 3859, 3860,
3861
pCAM7 yopB last 244 bp, 214
bp after yopD
pMRS101 Amp, Sm 3969, 3861
pCAM8 yopB last 244 bp, 214
bp after yopD
pKNG101 Sm
pCAM62 His10-YopB pBAD/HisB Amp 4885, 4886
pCAMP63 His6-G-G-A-G-G-YopB pBAD/HisB Amp 4886, 4887
pCAMP65 HAT-YopB pBAD/HisB Amp 4886, 4889
pCAMP66 His10-YopD pBAD/HisB Amp 3154, 4890
pCAMP67 His6-G-G-A-G-G-YopD pBAD/HisB Amp 3154, 4891
pCAMP68 His6-G-G-A-G-G-A-G-
G-A-G-YopD
pBAD/HisB Amp 3154, 4892
Table 5: Mutants and constructs used for purification of the translocation pore.
Complementation of mutants with His-tagged YopB or YopD
Secretion and hemolysis experiments to test complementation of the ∆HOPEMNB (MIPA 1516)
strain with the different His-YopB constructs and complementation of ∆HOPEMND (MIPA 2092)
and ∆yopD (MIPA 2091) with the different His-YopD constructs, were done as described before
(Goure et al., 2005; Mueller et al., 2005).
Immunoblotting
Immunoblotting was carried out using rat monoclonal anti-YopB (MIPA 98) and anti-YopD
(MIPA 96) antibodies and a mouse monoclonal anti-His antibody (GE Healthcare). Detection
was performed with secondary antibodies conjugated to horseradish peroxidase (1:2000; Dako)
before development with supersignal chemiluminescent substrate (Pierce).
Purification of the translocation pore
The ∆HOPEMND strain complemented with pCAM67 was used to infect RBCs followed by
membrane isolation as described previously (Goure et al., 2005). Expression of His-(G-G-A-G-
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G)-YopD (pCAM67) was induced by the addition of 0.2% arabinose after 1h of incubation at
37°C, followed by an additional 2h at 37°C.
Purified RBC membranes were solubilised in solubilisation buffer (20mM sodium phosphate,
500mM NaCl, 1% Triton X-100, pH 7,4) for 1.5 h at 4°C on a slow wheel. The sample was
loaded into a 2 ml sample loop and Ni2+-affinity purification was performed using three 1 ml
HisTrap columns (GE Healthcare) in a row on an Aekta purifier UPC900 (GE Healthcare) at a
flow rate of 1 ml/min buffer His A (20mM sodium phosphate, 500mM NaCl, 0.1% Triton X-100,
pH 7.4). After sample application the columns were washed with 2 column volumes 5% buffer
His B (20mM sodium phosphate, 500mM NaCl, 0.1% Triton X-100, 500mM imidazole, pH 7.4).
Bound proteins were eluted using a gradient of 5% to 100% buffer His B within 6 column
volumes. 1.5 ml fractions were collected starting at the injection of the sample on to the column
and precipitated with 10% v/v TCA at 4°C over night. The fractions were analyzed by Western
blotting using anti-YopD, anti-YopB and anti-His antibodies and by silver stained SDS-PAGE.
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3.5 The connector between the needle and the tip complex
Needles purified from an lcrV mutant strain (∆HOPEMNVQ), lack the tip
complex, and instead are distinctly pointed (cone structure) at one end,
indicating that there might be an additional protein at the needle tip, connecting
the tip complex to the YscF helix.
In silver stained SDS-PAGE, no additional proteins besides LcrV, YopD and
YscF could be identified so far. However, it is to be expected that the protein
forming the cone structure is not present in high amounts, and may be below
the detection limit of the silver staining.
There are several small Ysc proteins of unknown function encoded in the virC
and virB operon on the pYV plasmid (YscH, YscI, YscO, YscX), which could be
candidates for the formation of the cone structure.
3.5.1 Labeling of needles from ∆HOPEMNVQ with anti-YscF antibodies
To analyze whether the end of the YscF helix forms the cone structure, needles
purified from the ∆HOPEMNVQ strain were labeled with polyclonal anti-YscF
antibodies and visualized by STEM.
The antibodies only bound to the broken end of the needle, as observed
previously for wild type needles (Mueller et al., 2005). Labeling of the pointed
end of the needles with the anti-YscF antibody was not observed (Figure 19).
This result would be compatable with the presence of an additional protein at
the tip of the needle. However, another possibility is that the epitope recognized
by the anti-YscF antibody is only exposed at the broken end of the needle and
is buried within the structure at the pointed end.
Based on this experiment a clear conclusion concerning the nature of the cone
structure cannot be reached. Further analysis of the proteins in the purified
needle fraction and of needles from different mutants will be necessary to
resolve this point.
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Figure 19: Immuno-STEM using anti-YscF antibodies and needles purified from the
∆HOEPMNVQ strain. Negative staining with 2% PTA. Scale bars 20 nm.
3.5.2 Analysis of needles purified from the ∆yscH strain
YscH (= YopR) is a small, secreted protein encoded between yscI and yscG in
the virC operon of the pYV plasmid (Allaoui et al., 1995).
The pattern of proteins secreted at 37°C upon Ca2+ chelation by the kyscH
mutant is the same as the one of proteins secreted by wt bacteria. Although this
indicates that the needle is assembled and functional the mutant is attenuated
in virulence in a mouse model (Allaoui et al., 1995). The protease resistant core
of YscH shows a surprising structural similarity to one domain of YopN, but
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further insight into the function of YscH has not been gained (Schubot et al.,
2005).
Needles purified from the ∆yscH strain had a tip complex indistinguishable from
wild type (Figure 20). This indicates that YscH is not involved in the formation of
the tip complex and does not form the cone structure observed on needles from
the ∆lcrV mutant.
Figure 20: STEM analysis of needles purified from the ∆yscH strain. Negative staining with 2%
PTA. A) two needles superimposed onto a flagellar filament. B) Two needles. Scale bars 20 nm.
Materials and Methods
Needle purification (∆yscH: MIPA 1050, ∆HOPEMNVQ: MIPA 1519), STEM and Immuno-
electron microscopy experiments were done as described before (Mueller et al., 2005) using the
anti-YscF antibody (MIPA 223).
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3.6 Interaction of LcrV with YopB and YopD
Characterisation of the interaction between the tip complex protein LcrV and the
two hydrophobic translocators YopB and YopD is an important step on the way
to understanding pore formation in the host cell membrane.
3.6.1 Site-specific mutations in LcrV to determine the region of interaction with
YopB and YopD
The major differences between LcrV, AcrV and PcrV are restricted to the two
globular domains of the proteins. As described previously hybrid proteins
comprising either the N-terminal globular domain of LcrV or AcrV were able to
insert YopB into RBC membranes, whereas hybrids containing the N-terminal
globular domain form PcrV were not (Broz et al., 2007). This indicates that
differences in the N-terminal globular domain of the V-antigens are responsible
for the poor hemolysis observed with PcrV.
the goal was to identify amino acids involved in the interaction with YopB and
YopD by mutating residues in LcrV that are conserved in AcrV but not
conserved in PcrV. All of the LcrV mutant variants that are secreted and form a
tip complex but are not hemolytic would then be tested for their ability to bind
YopB and YopD.
Results and Discussion
LcrV,  PcrV and AcrV were a l igned us ing Clusta lW2
(www.ebi.ac.uk/Tools/clustalw2/index.html) and amino acids conserved in the
N-terminal globular domain of LcrV and AcrV but not in PcrV were mutated to
alanine. In addition, some charged and surface exposed residues were chosen
for mutagenesis (Figure 21).
A total of 14 different mutations were introduced into LcrV by overlapping PCR
and cloned into pBAD/mycHisA under the control of the arabinose promoter.
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Figure 21: Alignement of LcrV, AcrV and PcrV using the ClustalW2 alignment program
(www.ebi.ac.uk/Tools/clustalw2/index.html). The two alpha helices forming a coiled coil are
marked in yellow, residues mutated to alanine by site directed mutagenesis in LcrV are marked
in red.
All of the LcrV mutants complemented the ∆HOPEMNVQ strain for secretion of
LcrV and hemolysis; this indicates that the binding of LcrV to the YscF needle
and the interaction with YopB and YopD was not disturbed (data not shown).
Single amino acid substitutions or deletions are thus not sufficient to disrupt
LcrV function. Therefore these mutations could be combined in a next step.
Alternatively random mutagenesis could be performed on the N-terminal
globular domain, followed by a screen for mutants that have lost their hemolytic
activity.
3.6.2 Far-Western blotting to determine the LcrV domain involved in the
interaction with YopB and YopD
LcrV can be divided into four distinct domains. The N-terminal globular domain
(G1), a central globular domain (G2) and two long alpha helices involved in the
Results
57
formation of a coiled coil (A1 and A2). The interaction of the different domains
of LcrV with YopB and YopD was assessed by far-Western blotting.
Results and discussion
The individual domains and combination of different domains of LcrV were
cloned with a His-tag (Petr Broz, unpublished, Figure 22A) and tested for
expression ans secretion in Y. enterocolitica ∆HOPEMNVQ. Except for His-A1
(pPB56) all the LcrV variants were expressed, but only full length His-LcrV was
secreted (Petr Broz, unpublished). The His-tagged domains of LcrV were
purified by affinity on Ni2+-sepharose.
The interaction between the LcrV domains and YopB/YopD was analysed by
far-Western blotting. After induction of secretion the proteins from the culture
supernatants of MRS40 wild type and ∆HOPEMN, were separated on SDS-
PAGE and transferred to nitrocellulose membranes. The membranes were
incubated with equimolar amounts of the purified His-tagged LcrV domains and
bound proteins were detected with anti-His antibodies.
The interaction domain of LcrV with YopB and YopD could not be clearly
determined by far-Western blotting, since most of the constructs tested
interacted with YopB and/or YopD (Figure 22B). In addition there were also
some background bands, which can presently not be explained or clearly
attributed to a protein in the supernatant of secretion with which the tested LcrV
domains could interact.
It is likely that the interaction of LcrV with YopB and YopD is not restricted to
one domain of LcrV, explaining why similar results were obtained with all the
different constructs.
Due to the unclear results this approach was finally abandoned and overlays
using the hybrids were used to get further insight into the interaction of LcrV
with YopB and YopD (Broz et al., 2007).
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Figure 22: A) Constructs made for far-Western blotting experiments (Petr Broz) B) Far-Western
blots using supernatant of cultures from MRS40 wild type (lane 1) and ∆HOPEMN (lane 2) and
the purified His-tagged domains of LcrV. Control: Western blot anti-His
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Materials and Methods
Construction of plasmids
Amino acids at different positions in the N-terminal globular domain of LcrV were replaced by
alanine by overlapping PCR. The PCR products were digested with NcoI/EcoRI and cloned into
the NcoI/EcoRI sites of the expression vector pBAD/mycHisA (Invitrogen) resulting plasmids
pCAMPB42 to pCAMPB55 (Table 6).
Name Description Vector Selection Oligos used
pCAMPB42 LcrVY5A pBAD/mycHisA Amp 3807, 4611, 4612, 4594
pCAMPB43 LcrVN8A pBAD/mycHisA Amp 3807, 4595, 4596, 4594
pCAMPB44 LcrVP9A pBAD/mycHisA Amp 3807, 4597, 4598, 4594
pCAMPB45 LcrVEKVR17-20A pBAD/mycHisA Amp 3807, 4605, 4606, 4594
pCAMPB46 LcrV∆EKVR17-20 pBAD/mycHisA Amp 3807, 4588, 4589, 4594
pCAMPB47 LcrVQ37A pBAD/mycHisA Amp 3807, 4599, 4600, 4594
pCAMPB48 LcrVK42A pBAD/mycHisA Amp 3807, 4592, 4593, 4594
pCAMPB49 LcrVD55A pBAD/mycHisA Amp 3807, 4582, 4583, 4594
pCAMPB50 LcrVR62A pBAD/mycHisA Amp 3807, 4601, 4602, 4594
pCAMPB51 LcrVE69A pBAD/mycHisA Amp 3807, 4590, 4591, 4594
pCAMPB52 LcrVD92-G97A pBAD/mycHisA Amp 3807, 4603, 4604, 4594
pCAMPB53 LcrVT111A pBAD/mycHisA Amp 3807, 4607, 4608, 4594
pCAMPB54 LcrVT127A pBAD/mycHisA Amp 3807, 4609, 4610, 4594
pCAMPB55 LcrVD129A pBAD/mycHisA Amp 3807, 4584, 4585, 4594
Table 6: Mutagenesis of LcrV
The individual domains of LcrV with a His-tag for far-Western blotting were constructed by Petr
Broz (pPB48-57; PhD Thesis, December 2006) as described in the Mipalab.
Complementation of Y. enterocolitica ∆HOPEMNVQ (MIPA 1519)
Secretion and hemolysis experiments to test complementation of the ∆HOPEMNVQ strain
(MIPA 1519) with the different LcrV mutants were done as described before (Goure et al., 2005;
Mueller et al., 2005)
Alignements
Al igenement of  LcrV, AcrV and PcrV was done using ClustalW2
(www.ebi.ac.uk/Tools/clustalw2/index.html)
Protein purification
His-tagged proteins were expressed in E. coli Top10 and the cells were subsequently lysed by
sonication. The filtered cell lysate was passed over chelating sepharose and washed with 50
mM Tris, 500 mM NaCl, pH 8. Bound proteins were eluted with buffer (50 mM Tris, 100 mM
NaCl, pH 8) containing different concentrations of imidazole (0 to 500 mM). Proteins were
quantified by the Bradford assay
Far-Western blotting
Secretions using the MRS40 wild type and ∆HOPEMN strains were done as described before
(Mueller et al., 2005) and secreted proteins were separated by SDS-PAGE and transferred to
nitrocellulose membranes. The membranes were incubated with equimolar amounts of purified
protein (His-tagged domains of LcrV). Immunoblotting was carried out using a mouse
monoclonal anti-His antibody (GE Healthcare). Detection was performed with secondary
antibodies conjugated to horseradish peroxidase (1:2000; Dako) before development with
supersignal chemiluminescent substrate (Pierce).
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3.7 The secretion signal of LcrV
A major difference between T3S and the Sec dependent secretion pathway is
that the secreted proteins do not have a classical, cleavable N-terminal signal
sequence (Michiels and Cornelis, 1991).
The cyclase domain of the Bordetella pertussis adenylate cyclase (CyaA) was
used previously as a reporter to monitor translocation of effectors into
eukaryotic cells (Sory and Cornelis, 1994). Cya is not secreted by the T3SS
unless it is fused to the secretion signal of an effector, and is therefore a
valuable tool to determine the region of T3S substrates necessary for secretion.
Analysis of different effector Yop-Cya fusions showed that the signal sufficient
to direct secretion of the hybrid proteins lies within the N-terminus of the Yop
proteins (Schesser et al., 1996; Sory et al., 1995). However, no conserved
signal sequence was found by comparison of different effectors (Michiels and
Cornelis, 1991).
The secretion signals of the translocators LcrV, YopB and YopD have not been
analysed so far and is probably not the same as for the effectors. The
translocators are probably secreted before the effectors, in order to form the
pore in the host cell membrane. In addition, it has been shown that the basal
body protein YscU, which undergoes autocleavage is involved in substrate
recognition (Sorg et al., 2007). A YscU mutant in which autocleavage is
prevented, secretes the effector Yops but not the translocators, indicatig that
the translocators are recognized differently (Sorg et al., 2007).
Fusions between LcrV and Cya were analysed to determine the secretion signal
of LcrV.
Results and Discussion
cyaA  was cloned into the EcoRI/HindIII sites of the expression vector
pBAD/mycHisA (pCAMP24). By chance the cyaA gene was in frame with the
start codon in the NcoI site of the vector, which lead to the expression of Cya
with an additional 14 amino acids from the vector at the N-terminus of the
protein (added sequence: DPSSRSAAGTIWEF).
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Cya was expressed and secreted by Y. enterocolitica MRS40 wt, ∆HOPEMNV
and ∆HOPEMNVQ. Most surprisingly it was expressed but not secreted by the
T3S ATPase mutant ∆yscN. This implies that secretion of Cya is dependent on
a functional T3SS. Given these results this construct containing Cya is thus not
useful to find the LcrV secretion signal (Figure 23).
Figure 23: A) Schematic representation of pCAMP24. RBS stands for ribosome binding site of
pBAD/mycHisA, the start codon is marked in red, amino acids encoded are given in one letter
code and the beginning of the cya gene is coloured in blue. B) Anti-Cya Western blots of the
total cells and supernatant fractions after induction of secretion by low Ca2+.
cyaA was thus re-cloned without the addition of amino acids at the N-terminus
(pCAMP27). Cya was expressed in Y. enterocolitica MRS40 wt and
∆HOPEMNVQ but not secreted (Figure 24). These results show that the
addition of a few amino acids to the N-terminus of a T3S unrelated protein like
Cya, can be enough to allow secretion via the T3SS.
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Figure 24: A) Schematic representation of pCAMP27. RBS stands for ribosome binding site of
pBAD/mycHisA, the start codon is marked in red, amino acids encoded are given in one letter
code and the beginning of the cya gene is coloured in blue. B) Anti-Cya Western blots of the
total cells and supernatant fractions after induction of secretion by low Ca2+.
CyaA was then directly fused to the N- or C- terminus of LcrV resulting in
plasmids pCAMP28 (lcrV-cyaA) and pCAMP29 (cyaA-lcrV).
Both CyaA/LcrV fusion proteins were expressed but not secreted in the Y.
enterocolitica MRS40 wt and ∆HOPEMNVQ strains. Further, even expression of
the fusion proteins in the secretion deregulated mutant ∆lcrG did not lead to
their secretion (Figure 25). This indicates that fusion of the large reporter to
LcrV blocks secretion of the fusion protein completely. In addition expression of
Cya, Cya-LcrV or LcrV-Cya reduced the secretion of all the other effectors (data
not shown).
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Figure 25: Anti-Cya Western blots of the total cells and supernatant fractions after secretion
induced by low Ca2+. pCAMP27: Cya, pCAMP28: LcrV-Cya, pCAMP29: Cya-LcrV.
Materials and Methods
The cyclase domain of CyaA was amplified from pDIA2557, which contains cyaA with a stop
codon at position 1198. The PCR product was cloned into the EcoRI/HindIII sites or the
NcoI/PstI sites of pBAD/mycHisA giving plasmids pCAMP24 and pCAMP27, repsecitvely.
The lcrV-cyaA and the cyaA-lcrV fusions were made by overlapping PCR and cloned into the
NcoI/PstI sites of pBAD/mycHisA, resulting in plasmids pCAMP28 (lcrV-cyaA) and pCAMP29
(cyaA-lcrV; Table 7).
Name Description Vector Resistance Oligos used
pCAMP24 DPSSRSAAGTIWcya pBAD/mycHisA Amp 4367, 4368
pCAMP27 cya pBAD/mycHisA Amp 4454, 4455
pCAMP28 lcrV-cya pBAD/mycHisA Amp 4455, 4456, 4457, 4458
pCAMP29 cya-lcrV pBAD/mycHisA Amp 4454, 4459, 4460, 4461
Table 7: CyaA and CyaA/LcrV fusions
Secretion experiments
Secretion of the different Cya constructs by Y. enterocolitica MRS40 wt (MIPA 198),
∆HOPEMNV (MIPA1518), ∆HOPEMNVQ (MIPA 1519), ∆yscN (MIPA 1124), ∆lcrG (MIPA 1215)
was done as described before (Agrain et al., 2005).
Immunoblotting
Immunoblotting was carried out using a goat anti-Cya antibody (Santa Cruz). Detection was
performed with secondary antibodies conjugated to horseradish peroxidase (1:2000; Dako)
before development with supersignal chemiluminescent substrate (Pierce).
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4. Discussion
4.1 Structure of the tip complex
Structural analysis of the tip complex is critical to understand its function,
especially in the context of pore formation in the host cell membrane.
STEM mass per length measurements of Y. enterocolitica wild type needles
and quantitative immunoblots showed that 3-5 molecules of LcrV form the tip
complex (Broz et al., 2007). This estimation is quite rough but nevertheless a
model of the tip complex was proposed by fitting the crystal structure of LcrV
(Derewenda et al., 2004) into the average density maps obtained by STEM.
Rotational symmetry was assumed and the best fit was obtained with 5 LcrV
monomers (Broz et al., 2007). The stoichiometry of five LcrV is in agreement
with the model proposed by Deane et al. in which the LcrV tip complex was
modelled to continue the helix of the Shigella MxiH needle, which is composed
of five MxiH subunits per turn (Deane et al., 2006). In contrast to our proposed
model, Deane et al. assume that the LcrV complex continues the helical
symmetry of the Shigella needle instead of having rotational symmetry. The two
proposed models are fundamentally different at the molecular level but based
on the current experimental data it is not possible to decide which is correct.
There is however also the possibility that the same model does not apply to all
T3SS.
Similar to LcrV, the Shigella homolog IpaD was modelled to continue the helix
of the needle, leading to a stoichimetry of five IpaD in the tip complex (Johnson
et al., 2007). In this case continuation of the needle helix leads to significant
staggering of the individual IpaD molecules along the helical axis, resulting in a
different molecular interface between IpaD in position 1 and IpaD in position 4,
and thus a different molecular environment for position 5 (Johnson et al., 2007).
Since the hydrophobic translocator IpaB co-purifies with the needle and IpaD
and is predicted to have a similar structure to IpaD, it was proposed that IpaB
could fill the last position in the Shigella  tip complex instead of IpaD
(Veenendaal et al., 2007). It should be noted that none of the Shigella tip
complex was not based electron microscopy images. The Shigella tip complex
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appears to be difficult to visualise and compared to the LcrV tip complex lacks
the distinctive base region (Espina et al. 2006b, Sani et al. 2007). Comparison
of the LcrV and IpaD structures reveals that the large N-terminal globular
domain found in LcrV is highly reduced in IpaD (Derewenda et al., 2004;
Johnson et al., 2007), which could explain the structural differences between
the tip complexes formed.
Since LcrV has a dumbbell like structure with two globular domains of similar
size, it was not possible to determine the correct orientation of LcrV by simply
fitting the molecule into the electron density averages obtained by STEM. In
their model Deane et al. assumed that the N-terminal globular domain forms the
base of the structure (Deane et al., 2006). Analysis of hybrids between LcrV
and PcrV and LcrV and AcrV was used to experimentally determine the
orientation of LcrV in the Yersinia tip complex. In agreement with the orientation
proposed by Deane et al. the N-terminal globular domain of LcrV was found to
form the base of the tip complex.
Cryo-electron microscopy (cryo-EM) analysis, which has several advantages
compared to STEM, could help to gain a more detailed view and understanding
of the structure of the tip complex. In contrast to STEM and TEM, cryo-EM
samples are maintained in buffer and rapidly frozen in a thin layer of vitreous
ice, which reduces artefacts from drying and staining and allows imaging to high
resolution.
4.2 The cone structure, a connector between the needle and the tip
complex?
The tips of needles purified from an lcrV mutant are distinctly pointed (Mueller
et al., 2005). In addition, modelling of the LcrV tip complex leaves a pointed
cavity inside the structure (Broz et al., 2007). These observations promt the
hypothesis that an additional connector protein could be present between the
needle and the tip complex forming a cone like structure inside the tip complex.
A cone is necessary to bridge the symmetry difference between tip complex
and needle if LcrV does not continue the helix of the needle.
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If LcrV continues the helix of the YscF needle, the tip complex would appear
tilted on all needles due to the helical rise. Although STEM analysis of purified
needles showed some tilted tip complexes, in most cases the tip complex was
not tilted compared to the needle (Mueller et al., 2005). The tilt occasionally
observed was probably a drying or staining artefact.
No protein that could be involved in the formation of the proposed cone
structure, has been identified so far. However, two different ''cone mutant''
phenotypes can be imagined: The first possibility is that assembly of the needle
remains unaltered, but the needles resemble those of an lcrV mutant the
assembly of the tip complex being disturbed due to the absence of the cone
structure. The only small, secreted protein in the Ysc T3SS with unknown
function that is not essential for needle assembly is YscH. However, the
needles formed by the yscH mutant have a wild type tip complex, indicating that
YscH is not involved in the formation of the cone structure.
The second possibility is that the needle does not assemble in the absence of
the cone protein. In this case the cone protein would fulfill a dual role as
capping protein necessary for needle polymerisation and as connector between
the needle and the tip complex.
The three small, secreted proteins YscI, YscO and YscX are essential for
needle assembly, but very little is known about their function. YscX was found
to be a late substrate (Kerstin Mayland, Isabel Sorg, unpublished), indicating
that it is probably secreted after the translocators and is therefore probably not
involved in the formation of the tip complex. YscI is an early substrate and the
amount of YscI secretion is somehow linked to YscF. yscP mutant bacteria
produce extra long needles due to the absence of the molecular ruler, which
controls needle length. In this mutant more YscF is secreted due to the
formation of longer needles and for some unknown reason YscI secretion is
also increased, leaving the ratio between secreted YscF and YscI unchanged
compared to wild type (Kerstin Mayland, Isabel Sorg, unpublished). YscI could
serve as a kind of ''mobile cap'', which is constantly replaced during needle
polymerisation and only stays connected to the needle tip once the needle has
reached its final length. At this stage it would serve as an adaptor for tip
complex assembly. However, to date there is no experimental data to support
this hypothesis.
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The only thing known about the small, secreted protein YscO is that it is
required for needle assembly. This makes it a possible cap/cone candidate, but
further experiments are necessary to determine the role of YscO in T3S.
All in all the identification of the cone protein is difficult, since it is probably not
very abundant in needle fractions from wild type bacteria and was so far not
detected on silver stained SDS-PAGE. The two proteins YscI and YscO were
also not detected in the purified needle fraction by Western blot analysis
(Diploma thesis Catherine Mueller, November 2003). Further investigation of
the protein content of the purified needle fraction, possibly by mass
spectrometry is necessary to gain further insight into the nature of a possible
cap/cone protein.
4.3 Interaction of the LcrV tip complex with YopB and YopD
LcrV is a hydrophilic protein that is essential for pore formation in the host cell
membrane (Lee et al., 2000; Pettersson et al., 1999; Marenne et al. 2003). The
discovery of LcrV at the tip of the injectisome needle helps to understand of the
processes involved in the assembly of the translocation pore. The tip complex
serves as an assembly platform and allows the insertion of YopB and YopD into
the host cell membrane (Broz et al., 2007; Goure et al., 2005). At the same time
it is the connection between the needle and the pore that is vital for effector
translocation. In the absence of LcrV, YopB and YopD insert in to the host cell
membrane to some extent, but fail to form a functional pore (Goure et al.,
2005). We have also shown that the N-terminus of LcrV is important for the
membrane insertion of YopB (Broz et al., 2007). A hybrid protein, in which the
N-terminal globular domain of LcrV was replaced by the smaller N-terminal
globular domain of PcrV does not support membrane insertion of YopB. On the
other hand replacement of the N-terminal globular domain of LcrV by the larger
one of AcrV does not affect pore formation and insertion of YopB into the
membrane (Broz et al., 2007).
This shows that even though PcrV and AcrV can form a tip complex on the
Yersinia needle, in the case of PcrV this is not enough to allow functional
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interaction with YopB. Besides the obvious size differences between LcrV, PcrV
and AcrV, sequence alignment does not allow any specific conclusions where
the functional differences between the three proteins are concerned. Site
directed mutagenesis to alter residues conserved in LcrV and AcrV but not in
PcrV, did not influence the interaction of LcrV with YopB/YopD. However, in
these experiments only single amino acids were mutated in LcrV and probably
did not affect the overall structure of the tip complex drastically enough to alter
the interaction with the hydrophobic translocators.
To gain further insight into functional differences between the different
translocators the two hydrophobic translocators or all three translocators
together could be swapped between species. One would expect that PcrV
together with PopB and PopD introduced into Yersinia allows pore formation
and possibly even effector traslocation to occur. It would also be interesting to
see if LcrV together with AopB and AopD from Aeromonas can promote pore
formation to a similar extent as AcrV can together with YopB and YopD. These
ideas could no be perused because both expression of the translocator operon
from Pseudomonas and A e r o m o n a s  in a Yersinia translocator mutant
(Catherine Mueller unpublished) and complementation of a P. aeruginosa pcrV
mutant with LcrV or the PcrV-LcrV hybrid failed due to technical problems with
protein expression (Catherine Mueller, Petr Broz, Caroline Gebus,
unpublished).
An attempt to localize the interaction site for YopB and YopD in LcrV was made
by far-Western blotting using different purified domains of LcrV and the
secretion supernatant containing YopB and YopD. Unfortunately, the results
were inconclusive and all the individual domains of LcrV seemed to interact with
YopB and/or YopD.
Understanding the interaction of the tip complex with the hydrophobic
translocators is crucial and remains to be elucidated.
For Shigella it was proposed that the tip complex is formed by four copies of
IpaD and one copy of IpaB (Veenendaal et al., 2007). This hypothesis is based
on the observation that IpaD and IpaB co-purify and can both be detected at the
tip of the needle by immuno electron microscopy (Veenendaal et al., 2007).
However, there are also reports that IpaB only localises to the needle tip under
certain conditions (Olive et al., 2007). Whichever may be true the localisation of
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IpaB at the needle tip is strictly dependent on the presence of IpaD (Olive et al.,
2007; Veenendaal et al., 2007).
In Yersinia, YopD also co-purifies with the needle and LcrV, but it was not
possible to crosslink YopD to YscF or LcrV (Mueller et al., 2005). Needles from
a ∆yopBD strain appeared to have a wild type tip complex (Mueller et al., 2005).
Single yopB and yopD mutants have not been analysed so far but one might
expect the same results. Although evidence argues against it, at the moment it
cannot be finally excluded that yopD is part of the Yersinia tip complex. Since
the Ysc T3SS of Yersinia and the Mxi-Spa T3SS of Shigella do not belong to
the same family it is possible that the tip complexes are adapted to the infection
process of the individual pathogens and are therefore structurally and
functionally distinct.
Yersinia needles were always purified from bacteria grown in liquid culture in
the absence of cells (Mueller et al., 2005). In contact with cells, YopB and YopD
are secreted through the needle and probably immediately interact with the
LcrV tip complex to form the translocation pore. Under in vitro secretion
conditions, the interaction with LcrV may not be very stable and YopB and
YopD could detach and aggregate, which would allow them to be pelleted
together with the needle during the purification process.
4.4 The translocation pore
The next step towards understanding the effector translocation process in T3S
is without doubt the purification and structural analysis of the pore formed by
YopB and YopD.
Several attempts to achieve this goal by different goups in the field have proven
difficult (Ide et al., 2001; Schoehn et al., 2003). In all studies so far, the
translocation pore was reconstituted from purified proteins (PopB/PopD,
Pseudomonas aeruginosa; Schoehn et al., 2003) or from secreted proteins
(EspB/EspD, EPEC; Ide et al., 2001). However, it is likely that the pore formed
by purified proteins is not the same as the pore inserted into the membrane by
live bacteria.
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A new approach to purify the translocation pore for structural analysis using
His-tagged YopB and YopD in a hemolysis assay was attempted here. The
advantages of this approach are that the pore is inserted into the RBC
membrane by the bacteria and probably resembles the pore formed during the
infection process. However, the amount of YopB and YopD inserted into the
membrane was small. Further a lot of the His-tagged protein was lost during
affinity purification, indicating that the His-tag was either buried in the structure
of the protein or that the Ni2+-column was saturated by contaminating proteins
such as hemoglobin. Nevertheless, if purification conditions could be optimized,
this method appears suited for purification of the pore from conditions as close
to the in vivo situation as possible.
An interesting finding was that the elution fractions that contained small
amounts of His-YopD, did not contain detectable amounts of YopB. Instead
YopB was detected in the flow through fractions of the columns. This tends to
suggest that the interaction between YopB and YopD must therefore be too
weak to persist during purification, indicating that YopB and YopD possibly form
two separate rings rather than one mixed ring.
One could envision that YopD forms a first ring on the LcrV tip complex, which
would then interact with YopB. YopD is the less hydrophobic of the two
translocators and could act as an adaptor between the hydrophilic tip complex
and a hydrophobic ring formed by YopB. In this case YopB would have the
major interaction with the host cell membrane (Figure 26) and would not directly
interact with LcrV. The lack of YopB membrane insertion observed with the
PcrV-LcrV hybrid could be explained by a destabilisation of the interaction
between the hybrid tip complex and YopD, which in turn would not support the
efficient insertion of YopB into the membrane.
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Figure 26: Model of the interaction between the LcrV tip complex (dark blue), YopD (yellow)
and YopB (red). The dashed line indicates the channel running through the needle, tip complex
and translocation pore.
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A) Sequencing of the translocator operon of MRS40 wt
The translocator operon of MRS40 was amplified by PCR and AflII/PstI sites
were added. The PCR product was cloned into the NcoI/PstI sites of the
expression vector pBAD/mycHisA giving plasmids pCAM9 and transformed into
E. coli Top10. Mini-preps of two different clones (clone 1 and clone 8) were
used for sequencing using the primers listed in table 8 and shown in Figure 27.
Primer Primer binding position
1108 208-227 bp pBAD/mycHisA
3294 243-262 bp of sycD
3295 262-243 bp of sycD
3296 315-334 bp of lcrV
3297 334-315 bp of lcrV
3298 640-659 bp of lcrV
3299 659-640 bp of lcrV
3300 291-310 bp of yopB
3301 310-291 bp of yopB
3302 592-611 bp of yopB
3303 611-592 bp of yopB
3304 893-912 bp of yopB
3305 912-893 bp of yopB
3306 298-317 bp of yopD
3307 317-298 bp of yopD
3308 604-623 bp of yopD
3309 623-604 bp of yopD
3892 5’ lcrG
3893 3’ lcrG
4493 420-398 bp pBAD/mycHisA
Table 8: Primers used for sequencing of the Y. enterocolitica MRS40 translocator operon.
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Figure 27: Schematic representation of the translocator operon and the binding sites of the
primers used for sequencing. The numbers of the primers are given at the corresponding
positions. fw stands for sense, rv for anti-sense primers.
The sequences were assembled using Phred, Phrap and Consed
(www.phrap.org/phredphrapconsed.html; Ewing and Green, 1998; Ewing et al.,
1998). The sequences of the two different translocator operons were aligned
using the program DNA Strider 1.4f6 (see below).
The major differences between the translocator operon of Y. enterocolitica
22703 (pYV22703) and MRS40 (pYV40) lie within the lcrV gene in which an
insertion of 18 bases was found in the MRS40 translocator operon. Other
differences, mainly restricted to the exchange of one base, are found in sycD,
lcrV and yopB.
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Top line (lower case): translocator operon pYV22703
Bottom line (upper case): translocator operon pYV40
lcrG
lcrV
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sycD
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yopB
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yopD
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B) List of constructs
MIPA Name Description Vector Selection
pYV plasmids
2091 pCAM4001
∆yopD
pYV40 yopD
2092 pCAM4002
∆HOPEMND
pYV40 yopE21 yopH∆1–352 yopO∆65–558
yopP23 yopM23 yopN45 yopD
Clones
4088 pCAM3 yopB, 214bp after yopD pBluscript KS+II Amp
4089 pCAM7 yopB last 244 bp, 214 bp after yopD pMRS101 Amp, Sm
4090 pCAM8 yopB last 244 bp, 214 bp after yopD pKNG101 Sm
4129 pCAM9, cl.1 lcrG lcrV sycD yopB yopD pBAD/mycHisA Amp
4130 pCAM9, cl.8 lcrG lcrV sycD yopB yopD pBAD/mycHisA Amp
4131 pCAM11 pcrG pcrV pcrH popB popD pBAD/mycHisA Amp
4132 pCAM14 acrG acrV acrH aopB aopD pBAD/mycHisA Amp
4091 pCAM17 LcrVC278S pBAD/mycHisA Amp
4092 pCAM18 LcrVC278S, 330C pBAD/mycHisA Amp
4093 pCAM19 LcrV2C, C278S pBAD/mycHisA Amp
4094 pCAM22 LcrV228C, C278S pBAD/mycHisA Amp
4095 pCAMP24 DPSSRSAAGTIWcya pBAD/mycHisA Amp
4096 pCAMP27 cya pBAD/mycHisA Amp
4097 pCAMP28 lcrV-cya pBAD/mycHisA Amp
4098 pCAMP29 cya-lcrV pBAD/mycHisA Amp
4099 pCAMP30 LcrVC278S, S282C pBAD/mycHisA Amp
4100 pCAMP31 LcrVN232C, C278S, S282C pBAD/mycHisA Amp
4101 pCAMP32 LcrVD133C, C278S pBAD/mycHisA Amp
4102 pCAMP33 LcrVD133C, D203C, C278S pBAD/mycHisA Amp
4103 pCAMP34 LcrVH89C, C278S pBAD/mycHisA Amp
4104 pCAMP35 LcrVH89C, A209C, C278S pBAD/mycHisA Amp
4105 pCAMP36 LcrVC278S, D287C pBAD/mycHisA Amp
4106 pCAMP37 LcrVG233C, C278S, D287C pBAD/mycHisA Amp
4107 pCAMP38 LcrVN96C, C278S pBAD/mycHisA Amp
4108 pCAMP39 LcrVN96C, E205C, C278S pBAD/mycHisA Amp
4133 pCAM40 sycD yopB pBAD/mycHisA Amp
4134 pCAM41 sycD yopD pBAD/mycHisA Amp
4109 pCAMPB42 LcrVY5A pBAD/mycHisA Amp
4110 pCAMPB43 LcrVN8A pBAD/mycHisA Amp
4111 pCAMPB44 LcrVP9A pBAD/mycHisA Amp
4112 pCAMPB45 LcrVEKVR17-20A pBAD/mycHisA Amp
4113 pCAMPB46 LcrV∆EKVR17-20 pBAD/mycHisA Amp
4114 pCAMPB47 LcrVQ37A pBAD/mycHisA Amp
4115 pCAMPB48 LcrVK42A pBAD/mycHisA Amp
4116 pCAMPB49 LcrVD55A pBAD/mycHisA Amp
4117 pCAMPB50 LcrVR62A pBAD/mycHisA Amp
4118 pCAMPB51 LcrVE69A pBAD/mycHisA Amp
4119 pCAMPB52 LcrVD92-G97A pBAD/mycHisA Amp
4120 pCAMPB53 LcrVT111A pBAD/mycHisA Amp
4121 pCAMPB54 LcrVT127A pBAD/mycHisA Amp
4122 pCAMPB55 LcrVD129A pBAD/mycHisA Amp
4123 pCAM62 His10-yopB pBAD/HisB Amp
4124 pCAM63 His6-G-G-A-G-G-YopB pBAD/HisB Amp
4125 pCAM65 HAT-YopB pBAD/HisB Amp
4126 pCAM66 His10-YopD pBAD/HisB Amp
4127 pCAM67 His6-G-G-A-G-G-YopD pBAD/HisB Amp
4128 pCAM68 His6-G-G-A-G-G-A-G-G-A-G-YopD pBAD/HisB Amp
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